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Abstract 
 
With the work reported in this thesis, we aim to contribute to the field of computational 
drug discovery. With our program FlexScreen, we attempt to estimate the ligand affinity 
to a protein model by simulating the formation of protein-ligand complexes. In this 
approach, the affinity of a ligand to a protein is determined as the energetic difference 
between the energetically optimal protein-ligand conformation and the state in which 
protein and ligand are not interacting with each other. We show that our approach helps to 
identify good binding compounds in a large database of ligands. 
The structure of this thesis follows the chronology of our research efforts. We first started 
with testing the accuracy of our docking algorithm. To calculate binding energies in a 
good approximation, we first determine realistic protein-ligand conformations.   
In another study, we analyze the problem of protein flexibility and the shortcoming of 
using only one rigid protein structure for docking simulations. In large-scale database 
screens we compare the influence of rigid and flexible protein models with each other. We 
show that flexible protein models result in an increased reliability of the screen and in the 
identification of a higher number of good binding ligands. 
Receptor-ligand interactions are calculated using many approximations. In a further study 
we investigate, if the accuracy of binding energies could be improved by employing 
parameters obtained from quantum mechanical calculations. We show that by 
incorporating the results of quantum mechanical calculations for the receptor, the overall 
accuracy of the whole simulation can be increased. This is an important result for high-
throughput screening, because the time consuming quantum mechanical calculations can 
be performed separately in advance.  
We have thus developed a high-throughput docking approach which allows us to identify 
good binding ligands in large databases. Including protein flexibility by allowing the side 
chains to alter their conformations results in a more realistic model of proteins. Applied to 
docking simulations of databases, our approach is less biased to the rigid, experimentally 
measured protein crystal structure which gives us the possibility to discover more diverse 
good binding ligands. In addition, the overall accuracy of our approach is enhanced 
further by integrating quantum mechanical calculations into our description of the 
proteins. 
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Zusammenfassung 
 
Mit dieser Arbeit leisten wir einen Beitrag zum Forschungsfeld der rechnerunterstützten 
Medikamentenentwicklung. Mit Hilfe unseres Programms FlexScreen versuchen wir 
mittels energetischer Kriterien potentielle Wirkstoffe zu identifizieren. Für jeden 
Liganden aus einer großen Moleküldatenbank ermitteln wir anhand stochastischer 
Simulationsmethoden die beste Protein-Ligandenkonformation und bestimmen damit 
dann die Affinität des Liganden zum Protein.  
In einer ersten Studie untersuchen und belegen wir zunächst die Zuverlässigkeit und die 
Genauigkeit unseres Ansatzes. Für ein Protein-Liganden Dockingsimulationsprogramm ist 
es wichtig, dass experimentell gemessene Bindungsorientierungen des Liganden 
zuverlässig reproduziert werden können; dies ist notwendig, um zuverlässig die Affinität 
eines Liganden zu bestimmen. Wir zeigen, dass dies mit unserer Methode erfüllt ist.  
In einer weiteren Studie wenden wir uns dem Thema der Proteinflexibilität zu. Bindende 
Liganden können Konformationsänderungen der Proteinstruktur veranlassen. Besonders 
bei Protein-Liganden Dockingsimulationen stellen wir Nachteile fest, wenn die 
Proteinstruktur als unveränderliche drei-dimensionale Struktur angenommen wird. In 
unserem Ansatz werden die Konformationsänderungen des Proteins mittels Flexibilität in 
den Proteinseitenketten approximiert. Wir weisen nach, dass auf diese Weise 
zuverlässiger und genauer gut bindende Liganden erkannt werden können. 
Das Problem, dass häufig Proteine und Liganden sich mit traditionell verwendeten 
Methoden nur ungenau beschreiben lassen, behandeln wir in einer dritten Studie. Hier 
können wir zeigen, wie durch das Extrahieren von Parametern aus vorausgehenden 
quantenmechanischen Berechnungen die Genauigkeit der Affinitätsbestimmung erhöht 
werden kann. Für Protein-Liganden Dockingsimulationen konnten wir feststellen, dass es 
für diese Steigerung der Genauigkeit auch ausreicht, wenn nur das Protein mit solchen 
extrahierten Parametern beschrieben wird. Diese Methodik hat den Vorteil, dass 
langwierige quantenmechanische Berechnungen nur einmal für das Protein durchgeführt 
werden müssen und damit die Rechenzeit für die Protein-Ligand Dockingsimulationen 
unveränderlich bleibt. 
Mit unserer Arbeit haben wir erfolgreich "high-throughput" Protein-Liganden Docking-
simulationsmethoden entwickelt. Wir zeigen die Zuverlässigkeit unseres Ansatzes und 
den Vorteil unseres flexiblen Proteinmodells. Des Weiteren stellen wir eine Methode vor, 
die eine höhere Genauigkeit zur Bestimmung der Affinität von Liganden erlaubt. 
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Preamble
Diseases have been treated with medications for thousands of years. The effects of these drugs
were usually discovered over centuries by trial and error. Many drugs used today have been
discovered by such observations. However, as the cellular and molecular mechanisms behind
many diseases are increasingly understood new avenues for rational drug development emerge
and a systematic search for drugs began. Over time, newly developed techniques and an ever
increasing knowledge led to new, but complementary, strategies for drug discovery.
First, animals were used as models for the human organism. However, because many potential
drugs could not be adequately tested with animals, in-vitro experiments became more and
more important. In in-vitro experiments the activity of various chemical compounds on cells
or on specific proteins is measured in the laboratory. About thirty years ago computational
drug research started to complement experimental techniques.
The biological system of the human body is very complex and far from being fully understood.
Chemical reactions, electrostatic and chemical signals occur constantly in our organism. Com-
plex reactions are needed, for example, to maintain the cell, to react to signals and to convert
chemical energy. The central nervous system, to give just one example, controls the func-
tionality of the whole organism. It reacts to stimuli from the environment and maintains the
functionality of the organism by actively sending signals to the organs. The signal pathway
is either of a pure chemical nature or uses combined electric and chemical signals.
Proteins, the building blocks of the cells, participate in such reactions and fulfill a variety
of different functions in the human body. They act, for example, as catalysts and lower the
activation energies for chemical reactions; proteins with this functionality are called enzymes.
Proteins also work as signal handlers and respond in a particular way to specific small com-
pounds, i.e. small molecules also called ligands that bind to a protein. In that functionality
the proteins are referred to as receptors.
The major goal in drug research is to find ligands that influence the organism, unwanted cells,
viruses or alien bacteria in a way that will lead to desired effects. The inhibition of enzymes
or of receptors is a successful approach to influence the activity of the protein. By hindering
the naturally binding compounds to dock to the protein, one can stop the metabolic cascade
in which the protein is involved. For such purposes, drugs with a very high affinity, i.e. the
binding energy, to a protein are necessary. These drugs should bind stronger to the protein
than the natural compound that usually interacts with it.
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A good drug acts specifically on the target only; i.e. in thermal equilibrium the drug is bound
to the target at the active site of the protein, where the natural compound normally binds.
The affinity of a compound to a target can be determined as the difference in the free energy
between the bound and unbound state of a ligand and a protein. Experimentalists usually
measure affinities of proteins and ligands in the solution. By comparing the concentration of
bound and unbound molecules in solution, the affinity is expressed in terms of the concentra-
tion required to saturate the protein with a given probability. As an example, a good binding
drug has a concentration in the nanomolar range.
Most drugs discovered today are rather small (less than 100 atoms). However, there is still
a vast range of chemical possibilities to construct small compounds by connecting different
chemical elements with each other. Therefore, strategies were developed to search for suitable
compounds for specific targets, i.e. for finding suitable ligands that will bind to very specific
protein binding sites.
The wide field of computational drug discovery developed over time from a rather abstract
approach, using mainly statistical analysis, to a more and more concrete calculation of protein-
ligand interaction energies. This became feasible due to a deeper understanding of the cell
processes and due to the possibility to determine the three-dimensional structure of proteins
and protein-ligand complexes experimentally. The three-dimensional structure of proteins
can often be determined by analyzing the scattering pattern of X-rays on a protein crystal or
by the method of nuclear magnetic spectroscopy. Analyzing the scattering pattern of X-rays
on a protein crystal is the most common method and most accurate method to obtain the
structural information of proteins. Difficulties in this method stems from problems to create
crystals for a given protein.
For most solved protein structures, scientists deposit the measured three-dimensional struc-
ture of proteins and macromolecules, i.e. aggregates of large molecules, in a publicly available
database on the internet: the Protein Data Bank (PDB). Presently, this database contains
about 40000 entries of three dimensional information for protein structures. With the advent
of structural genomics more and more people are working on determining the structural in-
formation of proteins and measuring methods improve steadily, resulting in a steady increase
of the rate of new entries in the PDB database.
In addition, a large amount of three-dimensional information of small chemical compounds is
publicly available. Companies that provide the profitable service of synthesizing these com-
pounds allow scientists to use the three-dimensional information of the small molecules for
computational studies. Due to the availability of the structural information of many com-
pounds, a large library of ligands can be easily constructed allowing scientists to perform
‘computational drug experiments’ on a large-scale. Instead of screening many compounds
in the laboratory for a high affinity to a target, computational approaches are used to iden-
tify potential drug candidates. Virtual screening provides a very quick and an inexpensive
approach to pre-select promising drug candidates. Of course, the computationally identified
high-affinity compounds must be experimentally verified.
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With the work reported in this thesis, we aim to contribute to the field of computational
drug discovery. We attempt to estimate the ligand affinity to a protein model by simulating
the formation of protein-ligand complexes. In this approach, the affinity of a ligand to a pro-
tein is determined as the energetic difference between the energetically optimal protein-ligand
conformation and the state in which protein and ligand are not interacting with each other.
We show that our approach helps to identify good binding compounds in a large database of
ligands.
The ultimate goal of this project is to develop a high-throughput drug screening approach,
which can be used for large databases. Because one of our main objectives is computa-
tional efficiency, we are not free to use all possible methodologies for our approach. Many
presently available computational methods can not be employed to identify potential drug
candidates in large databases of chemical compounds because they are not sufficiently fast.
For this reason, we can neither use quantum mechanical calculations nor molecular dynam-
ics simulations, even though these methods very accurately model protein ligand interactions..
Proteins and ligands are no static objects in a living organism. Because of thermal acti-
vation energy, they are constantly in a state of motion. When a ligand binds to a protein,
both ligand and protein can change their conformation and adapt to each other. Proteins are
constructed of different amino acids which are joined together by peptide bonds. A succes-
sion of peptide bonds generates a main chain, or backbone, from which various side chains
project outwards. These side chains differ from one amino acid to the next. Conformational
changes of the side chains are local conformational changes. They do not alter the position
of the connected amino acids. Conformational changes of the backbone, however, also alter
the positions of the connected amino acids.
If we look at the structure of a protein-ligand complex as measured by crystallography, we
see it as if we were looking at one single frame of a movie only. As a result, we do not get the
whole picture, i.e. the whole information of the binding process. Consequently, if drug design
were based solely on this particular ‘frame’, it is not possible to describe the whole system
adequately, which prevents us from discovering all possible high affinity molecules. However,
because the complexity of simulating the system increases drastically with the number of
degrees of freedom of the system, conformational changes of the protein upon ligand binding
are usually neglected in high-throughput screening. Conformational changes of proteins upon
ligand binding can often be accounted for by changes in the side chain orientation. In our
approach, we allow selected side chains to change their conformation as a first step towards
treating protein flexibility. We show that with a suitable search strategy, the side chains can
adapt to the ligand during the docking simulation process.
The structure of this thesis follows the chronology of our research efforts. We first started
with testing the accuracy of our docking algorithm (see chapter 6). To calculate binding
energies in a good approximation, it is necessary to first determine a realistic protein-ligand
conformation. We show that with our approach we can reliably and reproducibly predict ex-
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perimentally observed binding orientations. In this chapter, we also discuss general problems
in protein-ligand docking and point out specific problems which are not yet captured with
our scoring function.
In the next chapter, we analyze the problem of protein flexibility and the shortcoming of
using only one rigid protein structure for docking simulations (see chapter 7). We imple-
mented the possibility of using flexible side chains in our approach. In large-scale database
screens we compared the influence of rigid and flexible protein models with each other. We
show that flexible protein models result in an increased reliability of the screen and in the
identification of a higher number of good binding ligands.
Receptor-ligand interactions are calculated using many approximations. In a further study we
investigated if the accuracy of binding energies could be improved by employing parameters
obtained from quantum mechanical calculations (see chapter 8). We show that by incorporat-
ing the results of quantum mechanical calculations for the receptor only, the overall accuracy
of the whole simulation can be increased. This is an important result for high-throughput
screening, because the time consuming quantum mechanical calculations can be done sepa-
rately in advance. The more accurate parametrization of the receptor can then be used for
in the classical screening application. The computational effort for the screening remains the
same, but the accuracy of the docking results increase.
We have thus developed a high-throughput docking approach which allows us to identify
good binding ligands in large databases. Including protein flexibility by allowing the side
chains to alter their conformations results in a more realistic model of proteins. Applied to
docking simulations of databases, our approach is less biased to the rigid, experimentally mea-
sured protein crystal structure which gives us the possibility to discover more diverse good
binding ligands. In addition, the overall accuracy of our approach can be enhanced further
by integrating quantum mechanical calculations into our description of the proteins.
Chapter 1
Introduction
Drugs work in many different ways in biological systems. Focusing on the human organism
I will introduce the main mechanisms of drug interactions in this chapter and also briefly
summarize the historic and present development of the rational design of drugs.
1.1 Drug activity
The human biological system, even the part which is already understood, is very complex. In
the following I will describe some general examples of why and how drugs act. For a more
complex, introducting, overview, the reader may consult the books of G.L. Patrick [128] and
A. Gringautz [57].
Pharmaceutical drugs can be classified in different ways: By the protein they bind to, by
their chemical structure or by their pharmacological effect. In the following, I will focus on
the function of the proteins, drugs interact with. Drugs often act on enzymes, which may
then perform a reaction or which are hindered at performing a reaction, or may also act on
receptors, which respond to a signal or are blocked to respond.
1.1.1 Drugs acting on enzymes
Enzymes are proteins that act as biological catalysts in the human body. Many complex
reactions required by our metabolism do not take place spontaneously under physiological
conditions. Enzymes have the ability to decrease the activation energy and consequently al-
low these reactions to take place at a lower temperature, as illustrated in figure 1.1. Enzymes
have an active site, to which substrates can bind. These substrates are the reactants of the
catalytic reaction which is performed by the enzyme. After this reaction all products are
released and the enzyme, which did not alter during or after the process, is ready to repeat
the cycle. Such an enzyme activity is illustrated in figure 1.2.
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Figure 1.1: Illustration of a chemical reaction with and without enzyme. The red curve illus-
trates a reaction without any enzyme activity. As illustrated, if an enzyme acts catalytically
at the chemical reaction (blue curve), the necessary activation energy to start the reaction is
significantly lower.
enzyme enzyme enzyme enzyme
Binding Reaction Release
Products
substrate
Figure 1.2: Illustration of a chemical reaction involving an enzyme. After a substrate has
bound (first and second picture from the left) a chemical reaction takes place. After the
reaction is completed, the products are released and the enzyme is ready for the next reaction
(first and second picture from the right).
1.1. Drug activity 7
Enzymes are very important for cell metabolism. They are specifically adapted to fulfill
certain tasks in the cell and thus keep the cell maintaining. Usually, one enzyme participates
only in one chemical reaction. The specificity of the enzyme originates from its unique three-
dimensional conformation [128].
Many enzymes, which are present in human cells, can not be found in bacteria or vice versa.
The cells of bacteria and human cells seem to be quite different. This fact is also one of the
starting points for eliminating, for example, dangerous bacteria in the human body. Using
specific tools (drugs), the cell processes of unwanted bacteria can be disturbed and the cells
can be killed by disrupting their metabolism. Penicillin, for example, acts just in that way. It
blocks enzymes, which bacterial cells need to maintain the bacterial membrane [155]. If their
activity is disrupted, the bacterial cell can not maintain itself and is stopped from multiplying
itself.
Because of these reasons it is important in drug discovery to investigate and understand the
metabolism and mechanism of these alien intruders in the human body, unwanted cells in
the biological system, and then search for strategies. If specific enzymes are recognized as an
integral part of a disease, they can be structurally resolved and one can search for drugs, that
would stop these enzymes to work.
Figure 1.3 illustrates this idea. If a drug has a stronger affinity to bind to the enzyme than
the natural substrate, the catalytic reaction can be stopped. Because the substrate does not
have the enzyme as a partner no chemical reaction can take place. If this chemical reaction is
important for the cell metabolism or for cell functions, the drug will lead to biological effects.
The described process and the illustration is only abstract and exemplary. There are different
ways to hinder an enzyme at working [15].
enzyme enzyme
substrate
drug
no reaction
drug binds
Figure 1.3: Illustration of drug activity upon an enzyme. Because of the bound drug (left
picture), the natural substrate can not bind and the enzymatic process is stopped (right
picture).
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1.1.2 Drugs acting at protein receptors
The endocrine and the nervous system are the two important control systems of the human
body. Receptors are an integral part of both systems. The endocrine system directly uses
chemical molecules as their messengers to cells. Of course these molecules should only deliver
their message to those cells they were sent to. Due to receptors, the addressee, i.e. the recip-
ient cell can be identified.
Likewise, receptors are also important for the nervous system. Nervous cells can not commu-
nicate directly with each other or with other cells (muscles or glands) by electric potentials.
They are interconnected by chemical synapses. However, instead of communicating through
electric impulses as signals are transmitted in neurons, they use neurotransmitters. An elec-
tric impulse causes many neurotransmitters to be released from the axon terminal to the
synapse. Receptors situated at the outside of the cell membrane of dendrites, have the task
to identify these molecules and transmit the message accordingly; they are an essential part
of the biological signal transduction.
Receptors, which are proteins situated in a cell membrane, fulfill different tasks:
• Information exchange between cells
• Regulation of the ion flow in ion channels
• Regulation of protein synthesis due to binding to DNA
The tasks of various receptors are so different from each other, that they can only be described
in an exemplary and abstract way. Figure 1.4 displays a possible signal pathway of hormones.
When a hormone finds its corresponding addressee, then it can bind tightly to the receptor,
cell
cell core 
receptor
cell
cell core 
receptor
hormone 
signal
bound hormone
Figure 1.4: Schematic representation of the signal pathway of hormones. If a cell has the
corresponding receptor to a hormone, then it can bind tightly to the receptor and a signal is
transferred into the cell (here to the cell core).
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as illustrated in the picture. In doing so the receptor alters its conformation slightly and a
secondary messenger inside the cell is released. Such a signal could activate, for example,
another receptor or enzyme, which could finally result in a new synthesis of proteins. In
contrast to the interaction with enzymes (see figure 1.2), messengers acting on receptors do
not change their chemical structure upon binding. Usually the binding energy is also not very
strong. After some time the messenger is released from the receptor and drifts away.
Receptors are essential for inter-cell communications, because polar compounds can not cross
the lipid bilayer of the membrane [15] and consequently no direct interaction within the inte-
rior of the cell is possible.
In the following, I will present two other examples to further illustrate the way signals are
processed by the receptor. Figure 1.5 displays a possible receptor-induced ion-channel open-
ing. Before a messenger molecule binds to the receptor, the relaxed receptor structure hinders
ions to flow through the channel. When the receptor structure is ‘activated’ due to the bind-
ing of the molecule, the receptor conformation changes which leads to an un-blocking of the
ion-flow. Sometimes the conformational change of the receptor can involve large parts of
the structure, but often slight changes of the receptor structure, for example changes in the
side-chain conformation, can have such an effect. Of course, this process could also happen
in the reverse order. Due to the binding messenger, the ion-channel may get blocked.
Again, if one can design drugs that fit tighter into the receptor pocket than a respective mes-
senger, the receptor can be successfully hindered to alter its conformation. In our example
consequently the ion-channel will not open due to the blocking of the opening-mechanism.
Many drugs work in such a way. Anesthetics, for example, reduce the excitability of nerves
in this manner [15] so that the patient does not feel the pain anymore.
membrane
receptor receptor
messenger
messenger
membrane
protein protein
of receptor
conformation change 
ion−channel closed
ion−channel open
Figure 1.5: Schematic illustration of how an ion-channel is opened by an induced conforma-
tional change of a receptor. Before the messenger binds to the receptor, the receptor structure
hinders ions to flow through the ion channel. After the messenger has bound, the receptor
changes its conformation, which leads, in this example, to an opening of the ion-channel.
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Figure 1.6: Sketch of how an induced conformational change of a receptor structure enables
enzymatic reactions to take place. Before a messenger is being bound to a receptor, the
active site of a neighboring enzyme in the cell interior is closed. If the messenger is bound to
the receptor, the receptor changes its conformation and induces an additional conformational
change of the enzyme. As a result the active site of the enzyme opens and substrates in the
cell interior can start a catalytic reaction.
Figure 1.6 illustrates how an enzyme in the cell interior is activated by a signal from the
cell exterior. A messenger molecule binds to a receptor and induces a conformational change
of the receptor. In this example the new receptor conformation also induces directly a confor-
mation change of a neighboring enzyme. Before the messenger was bound, the enzyme was
‘switched off’; the enzyme is inactive. Consequently no bio-catalytic reaction could start. Due
to the altered enzyme conformation, substrates can now bind to the active site of the enzyme
and start the catalytic reaction. The resulting products may lead to further reactions.
Mechanisms, following the abstract scheme of figure 1.6, controlled by many different types of
receptors are abundant in different human cells. For instance, the class of G-protein coupled
receptors (GPCRs) act in a similar way. However, instead of a direct enzyme alteration,
the receptor activates other proteins which then activate an enzyme for catalytic reactions.
GPCRs are involved in many different stimulus-response pathways from inter-cellular com-
munication to physiological senses.
Now drugs can be used to influence the signaling pathway of messengers. They can hinder
directly or indirectly a messenger from binding to the receptor and thus disconnecting the
signal-pathway.
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1.1.3 Bioavailability
It is crucial that a drug binds strongly to the receptor, but no matter how well a substance
binds, it is useless, if it can not be transported to the receptor. The field of pharmacokinetics
describes mathematically if, in which concentration and how quick a drug gets to the target
location and how and when it is removed from the human organism [15].
The most important processes in pharmacokinetics are abbreviated by the acronym LADME:
• Liberation (L): If the drug is in a solid phase, it first has to get dissolved.
• Absorption (A): To enter the blood stream the drug has to cross different barriers by
passive diffusion. These barriers are usually membranes in the duodenum. Highly polar
and large molecules have difficulties crossing the lipid bilayer membranes.
• Distribution (D): The bloodstream will not distribute the medicament equally in the
human body. Because of different barriers in the human organism (for example the
blood-brain-barrier), a drug may not reach some parts of the human organism. Conse-
quently, the drug concentration will be higher in some regions (organs) than in others.
Additionally, the molecule distribution often also depends on how good a drug flows
in the blood. Molecules that are too large will have difficulties to flow quickly to the
target and the chances of degeneration are higher.
• Metabolism (M): There are special enzymes in the human body that detect alien sub-
stances and convert them into products which are easy to excrete.
• Excretion (E) describes the process of how the drug leaves the human body.
Several methods have been developed that attempt to mathematically characterize the LADME
processes. Through statistical evaluation of known medicaments the Lipinsky rule of five [98]
characterizes already roughly which compounds have a chance to reach their target and which
not.
If difficulties arise by an oral intake of a medicament, other transport ways can be investi-
gated. Some drugs, for example, are injected locally. Presently, even research efforts progress
to develop transport vessels, which can bring non-solvable drugs to the target and release
them there.
In our research we are focusing on the protein-ligand interaction only. We want to help to
discover compounds that bind with a high affinity to a specific target. The transport of drugs
is not our main interest.
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1.2 Brief overview of rational drug discovery
Drugs are rather sparsely distributed in the chemical space of possible candidates [98]. It
would take too much time to blindly test every possible compound in sito. Therefore, differ-
ent drug discovery strategies were developed and refined over the last 100 years based on the
technology and resources of the time.
Modern drug research is often traced back to Emil Fischer. With his metaphor of ‘lock’ and
‘keys’, he gave the field of drug research the direction for the next century: Enzyme and
inhibitor ‘must join one another as lock and key to be able to exert a chemical effect’. [45].
Paul Ehrlich’s concept, which he formulated in 1913, was also important for further develop-
ments: ‘corpora non agunt nisi fixata’; which means that compounds that do not bind have
no biological effect.
The strategies of rational drug design can be divided into two different classes: Methods
that involve the knowledge of the three-dimensional structure of the active center of en-
zymes/receptors and strategies that do not require such knowledge of the protein [15].
The first class could not emerge before the 1970s. With the pioneering work of Max Ferdinand
Perutz [116] and Sir John Cowdery Kendrew [80], honored both with the Nobel prize in 1962,
methods were developed to determine the three-dimensional structure of macromolecules.
These methods progressed with the time and became more and more to a difficult routine.
In this section, I will briefly discuss the main strategies of the two classes.
1.2.1 Strategies without knowledge of the protein
In the search for well binding drugs, chemists attempted to extract useful properties of a
known binding compound in order to use this knowledge to find a good binding drug. With
the analogy of E. Fischer a new ‘key’ should be found by looking at the ‘key’ only. The idea is
that all binding compounds to one target are similar in some way. Even though not belonging
to the same ‘chemical family’, there is often a similarity in hydrophilic, hydrophobic, aromatic
or other properties present.
These properties, descriptors, are used to search databases of ligands for similarity. Over time
the descriptors became more and more complex: From one dimensional to three dimensional.
Now databases are even searched with the help of neural networks [183]. Especially the
pharmacophore model, a three-dimensional descriptor strategy, is widely used. This method
uses the three-dimensional orientation of functional groups (hydrophobic, hydrogen binding
groups and further) to describe a molecule [15] and then search for similarity in a database of
compounds. One of its problems lies in sampling the conformational space of the molecules
and aligning it to the pharmacophore. An additional problem is that the search based on
similarity applies only well to targets which do not change much their conformation upon
ligand binding.
In drug discovery, the search for new types of well binding ligand structure and the optimiza-
tion of those should be differentiated. When a promising ligand has been found, the newly
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found ligand structure, the lead structure, can be used as the starting point for further studies
to increase the affinity or the transport properties of the ligand to the target. By varying the
chemical constituents of the lead structure different new molecules can be synthesized and
tested. The optimization of these compounds is not only based on the interaction of the new
drug with the protein, but also on an improvement of the drug transport in the human body.
Hydrophilic and hydrophobic properties of molecules influence in what concentration they
reach certain regions in the human body [15]. With the method of quantitative structure-
activity relationship (QSAR) the molecule is decomposed in different groups each contributing
differently to a biological activity scale. The method allows to compare different well binding
analogs of a new lead structure and to optimize them for transport in the biological system
and therefore for the best biological activity.
1.2.2 Strategies employing knowledge of the protein
Such strategies, also called molecular docking, analyze the interaction properties of a small
molecule to a protein. The approaches can be differentiated by the strategy used for sampling
different protein-ligand conformations and for estimating how well a ligand can bind.
Molecular docking methods have been developed in the last thirty years. In the beginning
both protein and ligand were treated as rigid entities and binding was simply based on geo-
metric criteria; the programs searched for shape only [48]. But soon the importance of the
chemistry in ligand docking [151] and also of ligand flexibility was realized and several im-
proved strategies were developed.
I will now distinguish between two approaches: Molecular mechanics and fragment based
approaches.
Molecular mechanics based approach
At the beginning both ligand and protein were considered as rigid unities. Nowadays it is
common to allow for some degree of ligand flexibility during docking, i.e. some inherent ad-
justing to the protein environment. The protein on the other hand is usually kept rigid.
In molecular mechanics (MM) docking approaches (see chapter 4) the ligand as a whole is
simulated. Through a step by step process the ligand adapts to its environment and the
system energy is optimized by changing flexible bonds of the ligand and its orientation. The
available methods are distinguished by the scoring function that evaluates the binding energy
by a score and the search algorithm.
The scoring functions can be classified either in regression-based or interaction-based scoring
functions. The former indirectly uses information of known complexes. Through statistical
analysis distant-dependent potentials for different atom pairs or functional groups are con-
structed on the assumption that the individual contributions obey Boltzmann statistics. The
frequency with which a specific geometry appears is related to the energy of that geometry.
The advantage of statistical analysis scoring functions is that relationships can be evaluated,
which are either not fully understood or difficult to model in a classical approach. On the
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other hand docking failures, the reason why some ligands do not bind, may also be more
difficult to understand.
Interaction-based scoring functions are similar to MM force fields. Both describe the interac-
tion of the ligand with the protein by classical potentials based on physical interactions. The
protein-ligand interactions are rooted in physical principles and have problems with features
whose origins are not clearly understood. But even in this approach many interaction param-
eters are usually fitted to experimental data.
Using such scoring functions or force fields already solves one problem that pharmacophore
models have to face: The ligand deformation is treated in the same way as the interaction
of the ligand to the protein. Consequently, it is easier to estimate if the resulting docked
geometry is realistic or not.
Because the screening programs must be very fast to be applicable, different techniques have
been developed to speed up the search for the best protein-ligand conformation. Monte Carlo
methods (see chapter 3) are used frequently as are genetic algorithms, which is used in the
program Gold [73] for example.
Fragment based approach
Fragment based approaches use a different technique to sample the huge conformational
space of a protein-ligand complex. The ligand is separated into different fragments which are
separately docked to the protein and then finally assembled into the whole molecule again
[160]. Different strategies are used for the reconnection of the broken bonds. One very popular
approach is the incremental construction algorithm which is implemented into the program
FlexX [134]. This algorithm starts with docking a base fragment to the protein and then
sequentially adds the other fragments in energetic favorable directions [183]. The final protein-
ligand conformation is usually evaluated by an empirical scoring function to determine the
affinity of the ligand to the protein. This approach does not fully explore conformational space
of the ligand. However by concentrating first on a larger or quite characteristic fragment, this
strategy has proven to be successful and is, for example, intensively used on supercomputers
of the Bayer CropScience Deutschland GmbH.
Interestingly, the de-novo ligand design methodology is strongly linked to this approach.
Instead of screening a database of ligands, a totally new ligand is constructed by docking
fragments of a database to the protein.
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1.2.3 Recent developments
Over the years many rational drug discovery methods have been developed and are being used.
Search strategies without the knowledge of the protein structure are still very important. For
example, most membrane proteins are difficult to resolve. What is more, drugs can have
side-effects, i.e. they may also bind to not designated proteins. The strategies, that compare
molecules just by similarity, can help to quickly test drugs for potential unwanted effects. But
unfortunately these methods are not working successfully in cases, in which no good binding
compound is known, because the potential compounds can not be compared with already
known ligands.
With our work we aim to contribute to the molecular docking field. Up to now, conformational
changes of the protein structure are usually not considered for docking and are, if considered,
still on an experimental footing. The necessity to account for a flexible protein structure is well
known and published [24]. The present status regarding protein flexibility can be compared
to the time docking of flexible ligands emerged. At the beginning it was computationally too
expensive to allow for ligand flexibility. As a consequence, methods were developed to first
generate different ligand conformations and to then dock them rigidly to the rigid protein
structure [78]. Now ligand flexibility is standard in most methods but protein flexibility not.
As first methods to treat ligand-flexibility one approach to solve this problem is to generate
increases
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Figure 1.7: Illustration of possible side chain flexibility, as used by our program FlexScreen.
FlexScreen allows, for example, the side chain arginine a maximum of three degrees of freedom:
three dihedral angles are allowed to be changed. Possible dihedral angles depend on low energy
interactions of the side chain with itself and the environment.
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a set of different protein structures and then to dock flexible ligands to each of them.
Full protein flexibility for high-throughput screening is not yet possible at the moment, since
accurate and affordable simulation strategies are lacking. In our approach, FlexScreen, we
allow for full side chain flexibility (as illustrated in figure 1.7). We hope that using full side-
chain flexibility will enable us to describe the majority of conformational changes upon ligand
binding.
Chapter 2
Thermodynamics of Protein-Ligand
Association
In the previous chapter different mechanism of drug activity in the human organism were
characterized. In this chapter protein-ligand interactions are examined in a more theoretical
manner. The affinity of a ligand to a protein is the free energy difference between a ligand
bound to the protein and both being separated in solution.
Protein-ligand complexes can be structurally resolved by several methods: X-ray crystallog-
raphy and nuclear magnetic resonance measurements. The affinity of a ligand to a protein
is measured by stochastic observations: Either the binding processes are counted during a
period of time or macroscopic properties are measured. Usually experimentalists measure the
concentration difference between bound and unbound ligands in a protein-ligand solution.
Therefore, I will first relate the microscopic binding free energy with macroscopic properties
and then quantify the binding free energy. Because the binding free energy is difficult to
calculate for a specific protein-ligand system, necessary approximations and assumptions will
be also introduced and explained.
2.1 Thermodynamic Basis
Protein-ligand docking describes the interaction between a ligand and a protein in solution
under constant pressure P and constant temperature T. Systems under these environmental
conditions are described with the Gibbs free energy [137] as the corresponding thermodynamic
potential of the system
G = H − TS = E + PV − TS (2.1)
and the Gibbs free energy change ∆G = ∆E + P∆V − T∆S, with enthalpy H, energy E,
volume V, pressure P and entropy S.
The volumetric work PV in liquid systems is negligible, because the volume per molecule is
small and the pressure in these liquid systems is rather low; the value PV is usually less than
the thermal energy kT [41].
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In the following, I will neglect the marginal difference between H and E. Consequently, Gibbs
free energy and Helmholtz free energy are not differentiated and will here be referred to solely
as the free energy
A = E − TS. (2.2)
The thermodynamic equilibrium of a liquid system corresponds to the global minimum of
the free energy. Guided by experimental observations Anfinsen [5] formulated in 1962 the
hypothesis that the native structure of proteins, observed by X-ray scattering, corresponds to
the global minimum of the free energy. He showed that proteins spontaneously assume their
native structure.
The hypothesis of Anfinsen is well supported by experiments and has been directly applied
to computational studies of protein folding. In the case of medium sized proteins (40 to 150
amino acids) several stochastic studies show that the native state of the protein corresponds
indeed to the global minimum of the free energy of the system [145, 65].
In protein-ligand docking we assume the situation to be similar. We suppose that if the ligand
has bound to a protein, the system is in thermodynamic equilibrium. This enables us to apply
a thermodynamic methodology.1
In statistical physics the free energy is defined as the logarithm of the partition function Z,
obtained by an integration over the propability density states of the thermodynamic system
F = −kt lnZ = −β−1 lnZ, with β = 1
kT
. (2.3)
The propability density states ρ(X) obeys a Boltzmann distribution ρ(X) = e
−βH(X)
Z .
In general no defined ground state of thermal equilibrium has to exist. If the energy difference
between several lowest free energy states is smaller than the thermal energy kT and the
corresponding conformations to these minima differ widely from each other, then no ground
state can be defined. However, by assuming one unique global minimum of the free energy,
the free energy of the system can be expressed as an expansion around the ground state with
the free energy A0 at the minimum:
A = A0 − T (Swater + Sconformation). (2.4)
The free energy A is expressed as the sum of the energy at the groundstate A0 and additionally
the entropic contributions of water (Swater) and of the protein and the ligand (Sconformation).
If essentially only two states in the protein-ligand systems (bound and unbound ligand) exist,
it is a good approximation to determine the binding affinity by calculating the free energy
difference between these two states.
1The strong postulation of assuming the bound state as the state of thermal equilibrium is not necessary.
Membrane proteins, for example, have to be considered in the environment of the cell membrane, separately
in solution they are in a different conformation. Because we do not assume global structurally changes of
a protein upon ligand docking, we postulate that the protein conformation, we use for docking, corresponds
to a low free energy minimum taking also the environment into account. We consider the bound ligand as
a perturbation to the protein in its environment. Due to the docked ligand a new free energy minimum is
obtained, which can also lead to structural changes of the protein, whose energetic cost is not very high.
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2.2 Thermodynamic view of protein-ligand affinity
In the following, I will first relate the binding free energy of an individual ligand to macro-
scopic measurable properties, experimentalists can measure. Then, the binding free energy is
analyzed in detail.
A very dilute solution of proteins (P) and ligands (L) is considered. If the protein and the
ligand form a protein-ligand complex (PL) without the formation of any covalent bonds, such
a behavior can be interpreted as a reversible chemical reaction
P + L⇐⇒ PL. (2.5)
If the system is in thermal equilibrium, the reaction rate into both directions is the same.
An open system is considered that interchanges energy with a constant temperature bath.
Consequently, in thermal equilibrium the temperature and the pressure of the system are
constant. In thermal equilibrium the Gibbs free energy of the system, the corresponding
thermodynamic potential of the system has its global minimum. Thus, the differential of
the Gibbs free energy is dG = −SdT + V dP +∑
i
µidNi =
∑
i
µidNi = 0, with µi being the
chemical potential of particle type i, defined as ∂G∂ni (ni being the number of particles type i).
Using the Euler theorem the Gibbs free energy can be expressed as [105]
G =
∑
i
µiNi (2.6)
and the differential of the Gibbs free energy can be rewritten in the following form [105]:
dG|const T, p =
∑
i
µidNi =
(∑
i
νiµi
)
dλ = 0, (2.7)
being dNi = νidλ. Considering one complete reaction (νi = −1 for the products and νi = 1
for the reactant), the chemical potentials of reactant and products are equal at thermal
equilibrium: ∑
i
νiµi = 0 =⇒ µPL = µp + µL. (2.8)
With the Gibbs-Duhem relation, SdT − V dp +∑
i
Nidµi = −V dp +
∑
i
Nidµi = 0 [137], one
can show by an integration (in dilute solutions the osmotic pressure of one species is the same
as for an ideal gas [169, 40]) that each chemical potential can be expressed in the following
way
µi = µ0i + kT ln
pi
p0i
= µ0i + kT ln (V [i]) . (2.9)
µ0i is a reference chemical potential corresponding to the reference pressure p
0
i for one element
or as usual for one Mole of element type i and [i] = NiNref,iV =
φi
V is the fraction density of
species i at the reference volume V with the number fraction φi in relation to the reference
unit.
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The binding free energy of one ligand and a protein is the free energy difference of bound and
unbound state. According eq. 2.8 we express it with the reference chemical potentials
∆GPL−P,L = GPL −GP,L sep. = µ0PL − µ0P − µ0L. (2.10)
Combining eq. 2.10 with eq. 2.8, the binding free energy can be expressed in the macroscopic
properties of concentrations
∆GPL−P,L = −kT ln [PL]
V [L][P ]
, (2.11)
whereas the association constant is defined by concentration densities as
KPL =
[PL]
[P ][L]
= V
φPL
φPφL
. (2.12)
This equation relates the observable macroscopic properties to the binding free energy. Now,
the binding free energy will be expressed by the integral of state. In the following, KPL is
derived from thermodynamical arguments [101, 148].
However, instead of a solution of proteins and ligands, solely one ligand and one protein in
solution are considered. Instead of comparing concentrations, thermodynamic expectation
values are compared of being in the bound and in the unbound state in volume V. Thus, the
macroscopic observation value ‘concentration’ is related to averages over a sufficiently long
time of one protein and one ligand in solution.
In the dilute limit, V → ∞, the thermodynamic expectation values of the bound state have
the limit value of 1: φP = φL → 1. Thus, the association constant crosses over to the limit
value KPL = V φPL. I will now briefly summarize the determination of the bound volume
density and so the association KPL.
A system consisting of a ligand, a protein and water molecules, with NL, NP and NS atoms
respectively, has the total number of 3(NS +NL +NP )− 6 degrees of freedom. 3NS solvent,
(3NL− 6) internal ligand and (3NP − 6) internal protein degrees of freedom and 6 additional
degrees of freedom which correspond to the relative position of the ligand to the protein.
The coordinate system shall now be defined by placing the protein (P) at the coordinate
origin. Then, a particular configuration of the system is determined by the coordinates of
the solvent atoms rV , the position and orientation of the ligand L to P with (r,Ω) and their
internal coordinates qL and qP .
The interaction between L and P can be described by a potential of mean force (PMF) [101]
ω(r,Ω) = −
r,Ω∫
r=∞
〈
dU(rV,qL,qP , r′,Ω′)
d(r′,Ω′)
〉
dr′dΩ′, (2.13)
with the potential of the whole system U. The PMF ω(r,Ω) describes the reversible thermo-
dynamic work to bring the ligand L from infinitely far away to the position and orientation
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(r,Ω). This potential is independent of the solvent and internal molecular coordinates, since
they are already averaged over by a Boltzmann weighted integration.
C(r,Ω) shall be defined as a function that is 1 if the ligand is bound to the protein and 0
otherwise. As the criteria for a bound state, we define that ω must be significantly lower than
the negative thermal energy kT. Then the association constant can also be expressed as a
thermodynamic observable [101]
KPL =
1
8pi2
∫
C(r,Ω)e−ω(r,Ω)/kTdrdΩ. (2.14)
Eq. 2.14 is exact but difficult to calculate. Assuming that the potential energy surface around
the ground state of the system can be approximated by harmonic potentials, this assumption
helps to gain further insight [101]. Now the motions of the system can be described by a
multivariate Gaussian propability distribution with a covariance matrix of the coordinate
fluctuations σ = 〈(xi − 〈xi〉)(xj − 〈xj〉)〉. The potential of mean force can be rewritten as
ω(r,Ω) = ωmin + 12∆x
T F¯∆x, where x includes the remaining coordinates r,Ω, qL and qP
and the matrix F contains the elements Fij = kt(σ−1)ij [4]. Then eq. 2.14 can be expressed
with the factors of the fluctuations of each coordinate [101]:
KPL = e−βωmin
√
8pi3σxσyσz
σ3χ√
63pi
√√√√ |σ2L,bound||σ2P,bound|
|σ2L,free||σ2P,free|
. (2.15)
In order to understand the main binding contributions in a more qualitative manner, we
assume that the internal fluctuations are zero for the ligand and the protein and that the
PMF ω is a square well with a constant binding energy (E) with the width σx, σy, σz for the
x,y,z coordinates [148] and in total σ3coord = σxσyσz. Then, eq. 2.14 can be evaluated as
KLP = σ3coorde
−E/kT and (2.16)
according to eq. 2.11, the free energy change can be expressed by
∆A = E − kT ln σ
3
coord
V
. (2.17)
The free energy change is calculated as a sum of the PMF (E) and the translational entropy
of the whole ligand.
In case of the more general evaluation (eq. 2.15) ∆A also includes the contributions of the
internal vibrations of the ligand and of the protein (relative to the unbound state) and of the
fluctuation of the orientation of the ligand to the protein.
The important result is that it is thermodynamically sound to calculate the free energy change
as a sum of a thermodynamically averaged binding energy and an entropic contribution.
However, it has not yet been explained how the potential of mean force can be calculated in
practice. This will be discussed in the next section.
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2.3 Separability of the binding energy
In biomolecular force fields the potential energy of a system is decomposed into several energy
contributions (Coulomb energy, van der Waals energy, etc. [see section 4]). Even if this is
correct, with the above derivation it is not yet certain, if such a decomposition is also possible
for the free energy change ∆A. That this is possible, will be shown in the following.
The separation of the potential energy is now indexed by the variable i
USystem =
∑
i
Ui. (2.18)
Consequently, the canonical ensemble averaged configuration energy 〈USystem〉 is
〈USystem〉 = 〈
∑
i
Ui〉 =
∑
i
〈Ui〉. (2.19)
Also, the free energy change can be expressed by temperature derivatives of the mean binding
free energy [18, 19] (the kinetic free energy contributions result a constant and are therefore
neglected)
∆A =
∞∑
n=0
(−β)n
(n+ 1)!
∂n〈U〉β
∂βn
=
∑
i
( ∞∑
n=0
(−β)n
(n+ 1)!
∂n〈Ui〉β
∂βn
)
. (2.20)
Such a derivation is the formal justification for separating the free energy into different energy
contributions like Coulomb, van der Waals interactions, entropic contributions and many other
according to the separation strategy of the force field (see chapter 4).
2.4 Necessary approximations of the binding free energy
The purpose of our study is to develop a high-throughput screening tool for drug discovery.
We aim to calculate the binding free energy for as many ligands as possible in an acceptable
amount of time. Necessarily, such calculations can not be totally accurate.
Under these conditions, we restrict ourselves to approximate only the relative binding free
energy difference of ligands. Our approach should be able to rank good or bad docking ligands
for one specific target (protein) according to their binding free energy.
One problem when approximating the binding free energy change, as we have seen with eq.
2.14, is to calculate the covariance matrix of the coordinate fluctuations [101]. Such calculation
and analysis is nowadays standard. For example, it is included as an additional tool into the
molecular dynamics (MD) AMBER program [130]). But nevertheless of its availability, it is
very time consuming and is only then a good approximation to the entropic contribution, if
suitable for the system.2 High-throughput docking methods can estimate such contributions
2There are also other methods to determine the binding or relative free binding energy: Thermodynamic
integration [104] or free energy perturbation methods show promising results in that direction [125]. However,
both methods have the disadvantage that many different system configurations have to be simulated and
equilibrated. Another quicker and more general, but less accurate, approach is the linear interaction method
[6], which samples only the bound and unbound state. Also this methods shows promising results, when
properly parameterized [6, 20].
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only through empirical parameters. Presently they are simply neglected in high-throughput
docking programs [93, 114, 50, 74].
Due to the size of the protein cavity, also the size of the ligand is restricted and only ligands
of a similar size can dock well. We assume that entropic contributions at a specific protein
cavity are similar for different ligands. Under that assumption, the ligands can still be ranked
‘accurately’, according to their calculated binding affinity.
Nowadays, it is a common routine to use further docking programs for those ligands, which
are selected as promising good binding ligands by a high-throughput docking tool. Then,
these entropic effects can be taken into account more accurately.
2.4.1 Thermodynamic Cycle
The interaction of the solute with the solvent can have an important impact on the binding
affinity of protein-ligand interactions. The best way to treat the solvent in computational
calculations is to include the solvent molecules as additional entities in the protein-ligand
system (as in MD simulations). Again, such very accurate methods are also computationally
very time consuming.
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Figure 2.1: Illustration of the thermodynamic cycle. Two thermodynamic paths are shown.
The blue arrows indicate the path at which the ligand and the protein are solvated and are
getting bound in solution. The second pathway is sketched by the red arrows: Ligand and
protein are separately de-solvated and first bind in vacuum/gas phase. Afterwards the whole
complex is solvated again.
In the following, I will briefly introduce the thermodynamic cycle approach which determines
the potential of mean force ω(r,Ω) by a different pathway (see figure 2.1).
The underlying idea of the thermodynamic cycle is that ω(r,Ω) is path independent. In
figure 2.1 the upper line (blue arrows) describes the usual path: Ligand and protein are in
the solution and are being bound with the binding potential ωsolvated = ωmin. The red arrows
indicate the second path: Ligand and protein are first de-solvated, then they are bound in
the gas phase (or vacuum) with the potential ωgas and finally the protein-ligand complex is
de-solvated again (brought from infinity into the water solution).
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When each work, performed on each process, is energetically evaluated, then ωsolvated can
be also expressed in the following way:
ωsolvated = ωmin = −ωPsolvated − ωLsolvated + ωgas + ωPLsolvated. (2.21)
The thermodynamic cycle approach is a popular method, because usually it is assumed that
the binding conformation of protein and ligand is the same in solution and in vacuum. Since
in vacuum the docking simulations are by far more efficient than in solution, in which water
molecules would have to be considered, less computational effort is needed. If the solvent is
treated implicitly (see section 4.2), the solvation energies can be approximated in a compu-
tationally efficient manner.3
In many cases, it is justifyable to use such an approach, for example if the cavity does not
have a direct connection to the bulk solvent and also if upon ligand binding almost all water
molecules are removed from the cavity.
However, this is not a generally valid approximation. For example, the binding conformation
in gas phase and solution are considered as being identical. But in open pockets (widely
accessible to the bulk solvent) a favored binding conformation in the gas phase can be very
different from the binding conformation in solution.
3The thermodynamic cycle would be accurate, if methods like the thermodynamic integration methods
were used.
Chapter 3
Stochastic Optimization Methods
The native binding conformation of ligand and protein is usually assumed to be the global
minimum of the free energy of the system: ligand, solvent and protein.
In the research field of protein-ligand docking two important objectives are:
a) To determine the groundstate of the ligand-protein system (neglecting all the protein
and ligand entropic contributions)
b) To determine the free energy change upon binding at room temperature in order to
compare the binding affinity of different ligands with each other
In this chapter, I will discuss the simulation methods for reaching these objectives.
3.1 Monte Carlo Simulation
Monte Carlo (MC) and other simulation methods are used to determine thermodynamic
expectation values. For this purpose two approaches are often used. In kinetic simulations
the equation of motion of the system are solved and thermodynamic expectation values are
computed as time averages over the observables. In stochastic methods a chain of trajectories
is constructed such that the frequency of each state approaches its thermodynamic propability
for long simulation times. The Hamiltontian, which describes the microscopic state of a
system, can be separated into kinetic and potential energy components. Since the kinetic
energy contribution can be integrated to a separate constant, we do not have to consider it to
describe the system. Each configuration of the state q is occupied according to the probability
density distribution of the thermodynamic system
ρ(q) =
e−βH(q)∫
e−βH(q)dq
=
e−βH(q)
Z
. (3.1)
A thermodynamic expectation value 〈X〉 can be calculated by an integration over the whole
configuration space and weighted with the probability density distribution of each state,
〈X〉 =
∫
X(q)ρ(q)dq.. (3.2)
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3.1.1 Principles of Monte Carlo simulations
A Monte Carlo simulation is based on several ideas, which I will characterize briefly.
1. Stochastic process:
The dynamic deterministic process as employed in molecular dynamic simulations is
replaced by a stochastic process [142]. This fundamentally changes the simulation pro-
cedure. The Monte Carlo simulation can speed up the whole simulation, because the
iterative change of the system conformation is independent of a realistic physical con-
formational change which molecular dynamic simulations would have to mimic. On the
other hand, the construction of the next conformation is not as straightforward as in
molecular dynamics. The transition probability from one state to the next must reflect
the probability density of the two conformations. For a stochastic process, solely the
ratio of the two probability density states is important
ρ(Y)
ρ(X)
=
e−βH(Y)
e−βH(X)
. (3.3)
2. Importance Sampling:
A phase space of a complex system is very large. In theory, each system state has
to be evaluated to achieve the thermodynamic averaging of an observable X, as in eq.
3.2. However, this is computationally impossible. This is why, for MC simulations, the
simulation is focused on those regions of the phase space which are important for the
accuracy of 〈X〉. Consequently, the simulation concentrates on the low energy areas
of the conformation space, which contributes highest to the thermodynamic averaging
[62, 142]. In other words, Monte Carlo simulations are biased towards low energy
regions.
Monte Carlo simulations generate Markov chains (of first order) with special properties. For
these Markov chains the probability W (Y,X) for a system state X to go to state Y is
independent of all the previous conformations that have occurred before X [63].
As mentioned above the transition probability W (Y,X) has to obey certain rules, which I
will describe briefly
1. Norm:
∑
Y
W (Y,X) = 1 (3.4)
In a thermodynamic system each state has a certain probability density. Therefore the
sum of the probability transition to all possible states must result into the probability
one.
2. Ergodicity:
W (Y,X) > 0 (3.5)
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In principle, it must be possible to reach each state in the configuration space through
a Monte Carlo simulation.
3. Detailed Balance:
The thermodynamic system, we describe, is in thermodynamic equilibrium. This prop-
erty is described by the principle of detailed balance [142]. At equilibrium the transition
between two states takes place in both directions at the same frequency [88]
W (Y,X)ρ(X) =W (X,Y)ρ(Y). (3.6)
3.1.2 Algorithm of Monte Carlo simulations
Metropolis et al. [110] introduced a simple construction procedure to calculate thermody-
namic properties which obeys all the required rules. The transition probability W (Y,X) is
separated into two parts [63]: A selection probability T (Y,X) which proposes a move to go
from state X to state Y and an acceptance probability AC(Y,X) expressing the probability
of this move being accepted.
Now, we assume that we want to go from state X with energy E(X) to state Y with energy
E(Y). If E(Y) < E(X), then the new conformation is accepted with probability one to be-
come the starting conformation for the next MC step. On the other hand, if E(X) < E(Y),
then the acceptance probability for this MC step is AC(Y,X) = e
−βE(Y)
e−βE(X) , according to eq.
3.3. These two cases can be combined to
AC(Y,X) = min{1, e−β(E(Y)−E(X))}, (3.7)
which is also called the Metropolis criterium.
Using an MC simulation to calculate the thermodynamic observable, the observable is then
calculated by averaging over all visited states
〈X〉 =
N∑
i=0
Xi
N
. (3.8)
3.2 Related optimization techniques
MC simulations are a powerful tool to sample system conformations at low energies. However
for very complicated potential energy surfaces with many hills and valleys, a MC simulation
is likely to get trapped at some local minimum and computes incorrect thermodynamic prop-
erties.
Since in our approach we are solely interested in finding the global optimum of a complex
energy landscape, a standard MC simulation is less suited for our purposes.
In this section, I will introduce two other strategies which are better suited to locate the
global energy minimum. Both methods are implemented in our program FlexScreen.
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3.2.1 Simulated Annealing (SA)
The SA simulation technique [81] is a very useful algorithm for global optimization problems.
Annealing describes a process in which the temperature of a molten system is slowly reduced
starting from a very high temperature. The system is heated to allow the system to escape a
local energy minimum and by gradual cooling the system can reach its groundstate [96].
SA can be integrated into the MC simulations, for which a high temperature1 is slowly
reduced.
The challenge lies in finding an optimal cooling strategy. The temperature must be reduced
so slowly that the system is equilibrated at each temperature (adiabatic process). If the
temperature is cooled down to a temperature close to T=0 (β →∞), the acceptance criteria
allows only those transitions to the next system state, which are lower in energy than the
previous state (moves into the direction of the minimum)
lim
β→∞
AC(Y,X) = lim
β→∞
e−β(E(Y)−E(X)) → 0, if E(Y)−E(X) > 0. (3.9)
Optimal cooling strategies can be derived [54] and estimated [66]. However, these cooling
schedules take too much time for docking purposes. Therefore, we decided to use a geometric
cooling strategy: For each accepted SA step n we update the temperature βn with
βn = β0γn. (3.10)
β0 is the starting temperature and parameter γ is adapted to the desired length of the Markov
chain accordingly. This process is not adiabatic and does not guarantee finding the global
optimum. Because of this, we use the annealing procedure only for refinements of promising
protein-ligand-conformations.
3.2.2 Stochastic Tunneling (STUN)
The Stochastic Tunneling (STUN), a generalization of the optimization method SA, was de-
veloped by Wenzel et al. [177] and is well suited for optimizations of protein-ligand complexes
[144]. In SA, entrapments can be only avoided if a suitable cooling strategy is employed. In
STUN, the dynamical process corresponding to the formation of the protein-ligand complex
explores not the original, but a transformed potential energy surface (PES), which dynami-
cally adapts and simplifies during the simulation.
For the docking simulations we use the following transformation
ESTUN = 0.3 ln
(
x+
√
x2 + 1
)
, (3.11)
1In MC simulations the temperature is related to the probability density states of the configurational system
space. The configurational energies of the systems are described as potentials which are parametrized at a
specific temperature (in our study the body temperature). Therefore, if we speak of a high temperature,
we still assume that these properties of the system are valid and are not altered and that in changing the
temperature we solely change the acceptance criteria of MC simulations.
3.2. Related optimization techniques 29
-400
-300
-200
-100
0
100
200
Po
te
nt
ia
l e
ne
rg
y 
su
rf
ac
e
-1 0 1 2
System state 
-0,5
0
0,5
1
1,5
Ef
fe
ct
iv
e 
po
te
nt
ia
l e
ne
rg
y 
su
rf
ac
e
Figure 3.1: 1) The panel above illustrates a fictitious potential energy surface. This PES
is transformed with STUN to an effective PES. 2) At the lower panel two effective PES are
shown. The green curve shows the transformed PES under the assumption that the best
energy found so far is at the green dot in the PES above and the blue curve represents
the transformed PES in relation to the so far best found energy at the blue dot in the
untransformed PES above.
where x = γ(E − E0). E is the energy of the present conformation and E0 the best energy
found so far. The parameter γ controls the steepness of the transformation.
The general idea of this approach is to flatten the potential energy surface in all regions that
lie significantly above the best estimate for the minimal energy E0. Even at low temperatures
the dynamics of the system become diffusive at energies E À E0, independent of the relative
energy differences of the high-energy conformations involved (see figure 3.1). The transition
of the conformations on the untransformed PES then appear to ‘tunnel’ through energy bar-
riers of arbitrary height while low metastable conformations are still well resolved.
Applied to protein-ligand docking this mechanism ensures that the ligand can reorient itself
through sterically forbidden regions while remaining inside the protein pocket.
In relation to SA, STUN can be understood as a scheme which adapts the temperature to
the energy of the PES and the present best estimate of the energy.
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By a Taylor series of the metropolis criteria (eq. 3.7) and under the assumption that the
energy differences of the present to the next conformation is small
(γ∆ = γ (ESTUN (X)− ESTUN (Y))¿ 1), the STUN MC criteria can be rewritten as [177]
ACSTUN (Y,X) = min{1, e−βγeγ(E0−E(X))(E(Y)−E(X))}. (3.12)
Eq. 3.12 shows the relation to SA: The usual MC temperature is transformed to an effective
temperature βSTUN = βγeγ(E0−E(X)) for the present best estimate of the energy.
Chapter 4
Biomolecular Force field
With recent quantum mechanical methods [51] it is possible to calculate the binding energy
ωmin (see eq. 2.21) with high accuracy even for macromolecular systems. However although
possible, it is still computationally very extensive and thus not applicable for tasks such as
high-throughput protein-ligand docking or for calculations of thermodynamic properties of a
system.
Molecular mechanic simulations are an alternative approach which is by far less time consum-
ing. In molecular mechanics classical forces are used to describe molecular geometries and
energies. In the underlying scheme of the Born-Oppenheimer approximation the movements
of nuclei and electrons are decoupled and a molecular object is considered as consisting of
points, at the position of the nuclei, with the properties of mass and charge. Chemical bonds
are described by strings with specific string constants for different types of chemical bonds.
These approximations can be used to perform simulations of a molecular system [142]. Unlike
in quantum mechanics, the potential functions are parametrized empirically.
A general application of molecular mechanics (MM) depends on the validity of two underlying
assumptions.
1. The total molecular energy of a system is separable into different energy contributions.
2. The different energy terms with their distinct parameters are transferable from the
limited data they were parameterized for to all molecular systems under consideration.
4.1 Molecular Mechanic Interactions
In this section, I briefly explain the possible energy contributions of a general molecular
mechanic (MM) force field. A molecular system of N atoms has 3N-6 degrees of freedom
[105], assuming N ≥ 3. In MM the total energy of a system Etot is expressed as the sum of
bonded Ebond and non-bonded interaction energies Enbond [30]:
Etot = Ebond + Enbond (4.1)
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Figure 4.1: Illustration of different types of bonded interactions. 1-2 and 1-3 interactions
correspond to a stretching or bending of a bond or a distance. 1-4 interactions correspond to
interactions which involve a change of a dihedral angle.
4.1.1 Interaction of chemically bonded atoms
Interactions between chemically bonded atoms are described and named according to the
indexed atoms which may alter their position relative to the other indexed atoms: We dis-
tinguish 1-2, 1-3 or 1-4 interactions. All other interactions shall be defined as interactions of
non-bonded atoms, even though they might be part of the same molecule.
Figure 4.1 displays all the possible interactions of bonded atoms.
The 1-2 interaction or the bond stretching energy
The 1-2 (bond stretch) interactions are vibrations of the chemical bond. Force fields which do
not allow chemical bonds to break often use just a simple harmonic potential to approximate
the energy, which is necessary to alter the ideal bond length
E1−2 =
∑
i,jεS1−2
Dij(rij − r¯ij)2. (4.2)
Here, rij is the distance of these two atoms (position of the nuclei) and r¯ij and Dij are the
equilibrium distance and the ‘spring constant’ of the atom pair. Both parameters rij and Dij
have to be determined empirically or by quantum mechanical calculations.
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The 1-3 interaction or the angle bending energy
The molecular bond angle depends on the overlapping molecular orbitals of bonded atoms
which is defined by an ideal angle θ¯. θ¯ can be calculated with the Hartree-Fock method [47] or
the related molecular orbital theory and is determined by the type of chemical bonds between
the atoms and also the orientation of the valence electrons.
1-3 interactions evaluate the difference in the conformational energy if angle θ differs from θ¯
E1−3 =
∑
i,jεS1−3
Aij(θij − θ¯ij)2. (4.3)
The harmonic approximation is again the most simple assumption. If the bending energy
is approximated more accurately (like the MMFF force field [61]), terms of higher order are
included.
The 1-4 interaction or the torsional energy
The 1-4 interaction describes the energy effort to rotate atom 4 around the bond of atom 1
and 3. In molecular mechanics force fields, such rotations are often described in the following
form
E1−4 =
∑
i,j,k,lεS1−4
∑
n
Rijkl,n
2
(1± cos[nΦijkl]) . (4.4)
Eq. 4.4 above is very general. The potential is expressed as a Fourier series of angle Φ. In
most force fields n ε 1, 2, 3 which means that there are no more than 3 energy minima during
a full 360◦ rotation. Rijkl,n is the associated barrier height which depends on the connected
chemical elements and n.
The origin of the barriers in internal rotations is often traced back to the interactions of the
Pauli-repulsion and Coulomb-interaction of the nearest neighbors. The AMBER force field
[130], for example, mixes the 1-4 bonded and non-bonded interactions by applying both a
torsional term and a scaled down non-bonded Coulomb term.
In recent investigations [176, 131] the energy barriers are referred to as a form of hypercon-
jugative ‘resonance stabilization’ for the electrons of σ-type single bonds. These bonding
electrons can delocalize and lead to a different binding pattern: a resonance structure be-
tween double and single bonds. Under this assumption, the minima in the torsional energy
conformations have their origin not due to release steric repulsion, but to achieve optimal
resonance stabilization.
Cross-Terms
The different interactions may also be interdependent. For example, due to a bending of a
chemical bond, the bond length can change. This effect can be considered to be corrections
to the harmonic approximations of the different potentials.
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4.1.2 Experimental parametrization
As mentioned before, unlike in QM, in molecular mechanics the interaction potentials need
to be properly parametrized. The so-called bonded interactions are usually fitted to vibra-
tional spectra of the atoms. The spectra can be measured by infrared spectroscopy or Raman
scattering [142].
Since not every atom in every molecule can be parametrized individually, atom types are
introduced. Different chemical elements may possess several atom types, differing in which
chemical bond the atom is participating in. The classification into different atom types de-
pends on the hybridization, bond strength, bond angle of the chemical element. For simplicity,
I will describe the mapping of atom i to its atom type by the general function ga−type(i) .
4.1.3 Interactions of non-bonded atoms
By definition all interactions which are not part of the bonded-interactions are considered as
non-bonded, even if these atoms are part of the same molecule. Interactions of non-bonded
atoms are usually understood as point-like interactions.
Lennard-Jones potential
2 3 4
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van der Waals attraction
ε
Figure 4.2: Lennard-Jones potential and its two constituents: Pauli repulsion and van der
Waals attraction. The well depth ² is indicated additionally.
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ELJ−6−12 =
∑
i,jεSLJ−6−12
4εij
[(
σij
rij
)12
−
(
σij
rij
)6]
(4.5)
ε is the well depth of the potential and σij determines the equilibrium position between the
two atoms. The shape of the Lennard-Jones potential, illustrated in figure 4.2, arises from
a balance of attractive and repulsive forces between two non-bonded atoms. The attraction
forces are of a long-range, whereas the repulsive forces are of a shorter range.
In the 1930s London [99] showed that the attractive forces are due to fluctuations in the charge
distribution of the atoms. The charge fluctuation of an atom can result in temporary dipoles
which cause dipole-dipole or dipole-induced-dipole interactions. These interaction lead to the
so called ‘London forces’ or van der Waals attractions illustrated in figure 4.2. London showed
that these interaction energies are proportional to r−6.
On the other hand, the short-ranged repulsive forces arise from the Pauli repulsion. The Pauli-
exclusion principle states that no two fermions are allowed to occupy the same quantum state
at the same position. These interaction energies are approximated with a term proportional
to r−12 [96].
Eq. 4.5, the Lennard-Jones potential, describes these two interactions in a combined form.
The Lennard-Jones potential is often used due to the mathematical simplicity, even if it is
only partly correct. The repulsive part is too large in comparison to experimental results.
In order to increase accuracy some force fields use the Buckingham-potential [96] with a
replaced repulsive term
EBuckingham =
∑
i,jεSLJ−6−12
[
−Aij
r6ij
+Bije−B
′
ijrij
]
(4.6)
Although this potential is more accurate than the Lennard-Jones potential, it has the disad-
vantage of becoming attractive for very small values of rij ; but this problem can be overcome
by correction terms.
The Lennard-Jones potential has its energetic minimum at rij = 2
1
6σij . The values of εij
and σij are atom or atom-type specific. In many force fields these parameters are defined for
interactions of the same atom-type (εij = εga−type(i)ga−type(j) = ε
aa and σij = σaa 4.1.2).
If interactions of different atom types are considered, these parameters can be calculated by
εab =
√
εaaεaa (4.7)
σab =
√
σaaσbb. (4.8)
Coulomb interaction
Amolecule is constructed of different elements, which are covalently bonded. Because different
elements attract their electrons differently strong, electronegative elements attract electrons
more than elements, which are less electronegative. This results in an unequal charge distri-
bution in the molecule, which can be represented in different ways [96]. One common way is,
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to arrange the charge distribution as fractional point charges, positioned at the nuclei of the
atoms. These point charges are arranged in such a way, that they reproduce to some limit
the electrostatic properties of the molecule.
Many different methods are proposed to calculate the point charges. Because we want to
process hundreds of thousands of ligands, we often use the point charges calculated with the
force field of ESFF [149] and of Gasteiger-Marsili [53]. These methods do not employ quan-
tum mechanical calculation for each molecule, but have different atom type parameters like
the electronegativity and determine the final charge distribution iteratively.
The interaction Vij between two charges qi and qj , which are separated by a distance of rij
in a medium with the dielectric constant ²r, can be calculated according to Coulomb’s law
ECoulombij = k
qiqj
²rrij
(4.9)
The parameter k is the electrostatic constant and ²r is the relative dielectric constant, de-
scribing the effect of the neighboring medium. In force fields which include explicitly water
molecules, the parameter ²r is constant for the whole system and depends only on the specific
implementation of all the other MM potentials.
Other force fields treat the water molecules implicitly, which has the great advantage that by
far less particles have to be simulated and approximate results can be achieved much quicker.
But these approaches need also a more complicated description of the system (see section
4.2).
The relative dielectric constant ²r was traditionally introduced to describe the polarizability
of bulk materials. If water molecules are locally entrapped in the protein interior, these water
molecules are difficult to treat implicitly by solely using a higher dielectric constant. These
water molecules can strongly influence the dielectric constant in the protein interior.
All these influences are the reason that ²r is not a constant of the system, but is rather de-
pendent on the position and on the conformation of the solute.
Nevertheless, for densely packed proteins a relative dielectric constant of about ²r = 1− 4 is
often used. The bulk solvent has a dielectric constant approximately of ²r = 80, which is in
agreement with experimental results [118].
Hydrogen bonding
A hydrogen bond is a special type of a dipole-dipole interaction. This interaction is of an
intermediate range between an electron deficient hydrogen and an atom with high electronic
density [90].
Such interactions play an important role for stabilizing the secondary structure, β-sheet or α-
helix, of a protein and between protein and ligands. For example, in rational ligand design one
approach is to modify the ligand structures to optimize possible hydrogen bond interactions.
This results often in an increased affinity of the ligand to the protein [179].
Hydrogen bonds can be defined by energetic, but also by structural criteria [90]: A bond
between a hydrogen (H) and an more electronegative element (X) results in a bond distance
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Θij
atom i
atom j
Figure 4.3: Illustration of the hydrogen bond interaction. Our scoring function uses a hydro-
gen bond potential, which depends on the direction of the hydrogen i to the acceptor atom j,
measured by the angle θij .
which is significantly smaller than the sum of their van der Waals radii.
Because hydrogen bonding is still difficult to model with a classical potential, it can only
be quantified in a very approximate manner. In most of the MM programs [130], it is often
described only by a dipole-dipole interaction, of the involved atoms.
We have therefore introduced an additional direction dependent potential which depending
on the direction replaces the Lennard-Jones potential of eq. 4.5.
EHB = cosΘij
(
R˜ij
r12ij
− A˜ij
r10ij
)
+ sinΘij 4εij
[(
σij
rij
)12
−
(
σij
rij
)6]
(4.10)
If Θij = 0 the hydrogen potential EHB replaces completely the LJ-potential. On the other
hand if Θij = 90◦, then only the usual LJ-potential is used.
A similar potential is also used by the program AutoDock [114].
As mentioned before, it is very difficult to energetically evaluate different hydrogen bond
geometries by classical potentials. We notice that other factors (for example the angle that
evaluates how good a bond is in one plane or the dipole-dipole angle) are important. Presently
quantum mechanical calculations are necessary to do such an evaluation accurately [86]. It
is too difficult to treat hydrogen bonding between different chemical partners with only very
simple rules for a detailed comparison.
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4.2 Treatment of the solvent
As discussed before, it is difficult to approximate the solvent contribution implicitly. In dock-
ing simulations we want to approximate the potential of mean force (PMF) ω(r,Ω) of eq. 2.13
between protein and ligand. This potential is partly calculated by an Boltzmann weighted
average over all possible solvent distributions at temperature T.
Implicit solvent models decompose this potential into a solvent independent potential ω(r,Ω)ipt. v1
and solvent dependent PMFs 〈Uvv〉 and 〈Uuv〉:
ω(r,Ω) = ω(r,Ω)ipt. v + 〈Uvv(r,Ω)〉+ 〈Uuv(r,Ω)〉 = ω(r,Ω)ipt. v +∆B(r,Ω), (4.11)
with the indices u for the solute and v for the solvent. As for the method of thermodynamic
integration [104], the reversible thermodynamic work to insert the solute into the solvent can
be calculated by
∆B(r,Ω) =
λ=1∫
λ=0
dλ
〈
∂ (Uvv(r,Ω) + Uuv(r,Ω, λ))
∂λ
〉
Ω,r=const
, (4.12)
with λ being the coupling parameter that describes with λ = 1 a full solute solvent inter-
action and with λ = 0 no such interaction at all. Uvv is the potential which describes the
solvent-solvent interaction. In our consideration, this potential is independent of the solute
and thus is the same for different solutes. Because we are only interested in binding affinities,
we neglect this contribution.
∆B(r,Ω) can now be further decomposed into non-polar (∆Bnp(r,Ω)) and electrostatic con-
tributions (∆Belec(r,Ω))[138]. Then each different contribution can be calculated in the
manner of the thermodynamic integration 4.12.
4.2.1 Non-polar contribution
Analytical derivations with the scaled particle theory [135] and computer simulations with
explicit solvent molecules show that the contribution of Bnp(r,Ω)) is approximately propor-
tional to the solvent accessible surface area [97] (SASA) of a solute which exceeds a specific
length scale [7]. Instead of simulating a whole system with explicit water molecules, it is pos-
sible to quantify the non-polar contribution Bnp(r,Ω) of a solute by calculating the SASA2.
1This potential is not the same as calculating the potential in the gas phase. Other enthalpy contribu-
tions can well be dependent on the averaged solvent; the environment of the present solvent influences other
interaction energies.
2Actually Su et al. [158] showed by studying dimerizations of alanine dipeptide that the non-polar contri-
bution can be better approximated by the sum of a non-polar cavity creation and the solute-solvent van der
Waals interaction, which are parametrized separately. The solute-solvent dispersion energies have a medium
range and it seems that they can not be neglected for an accurate calculation of Bnp(r,Ω)). We argue that
for protein-ligand docking the van der Waals interaction contribution can be neglected. Because ligands are
rather small molecules, the energy inaccuracy by incorporating the dispersion energies into the SASA term
should also be little.
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Figure 4.4: Illustration of the solvent-accessible-surface area (SASA). SASA is defined as the
trace of the center of a water molecule rolling over the contact surface of the molecule.
As shown in figure 4.2.1, the solvent accessible surface area is defined as the trace of the center
of a water molecule rolling over the contact surface of the molecule. The water molecules is
assumed to be a sphere with a radius of 1.4 A˚. Under this assumption the non-polar thermo-
dynamic work to insert a solute into the solvent is expressed as
∆Bnp(r,Ω) = γSASAtotal. (4.13)
γ is a surface tension term with the dimension of energyarea .
The entropic effect of mixing different particles can be neglected (Flory-Huggins-theory [46]),
for very dilute solutions.
4.2.2 Electrostatic contribution
The second term ∆Belec(r,Ω) can be similarly calculated by assuming a linear response of the
solvent to the charge distribution of the solute. By thermodynamic integration this results in
∆Belec(r,Ω) =
1
2
〈
U elecuv (r,Ω)
〉
. (4.14)
Continuum electrostatics offer an approach to calculate these interaction energies, without
an explicit representation of the solvent particles. The averaged solvent is replaced by a
featureless dielectric medium with a constant relative dielectric scalar ²v and a specific ionic
strength. Additionally, a constant relative dielectric scalar ²u is assumed for the volume of
the solute. Such approaches have been successfully applied for long and originate from the
well known scientists Born [17], Kirkwood [82, 159] and Onsager [124].
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It can be shown that the influence of ions in the solution to solvation energies and intra-
molecular electrostatic interaction, also between the ligand bound to a protein, is small and
can be neglected [59]. This is why for all further (and also the previous) considerations we
do not consider ions in the solution.
For the purpose of calculating the electrostatic contribution ∆Belec(r,Ω), the Poisson equa-
tion of the system has to be solved [71]
O [²(r)φ(r)] = −4piρ(r) (4.15)
and the electrostatic energy is computed using this potential [140]:
Eelec =
1
2
∫
<3
ρ(r)φ(r)dr =
1
8pi
∫
<3
~D2
²(r)
dr =
∑
i
1
8pi
∫
<3
~D2i
²(r)
dr+
∑
i<j
1
4pi
∫
<3
~Di ~Dj
²(r)
dr. (4.16)
Here, we label the charge density ρ(r), electrostatic potential φ(r) and the displacement field
of the different charges i ~Di. Thus, ∆Belec(r,Ω) can be considered as the correction to the
case of calculating the electrostatic energies solely with a dielectric constant of ²u.
Several numerical solution for solutes of arbitrary shape and charge distribution are available.
Programs like APBS [8] or Delphi [121] use finite element techniques to discretize the system
and solve the Poisson-Boltzmann equations iteratively. They are very accurate, but still too
slow to become a general solution for high-throughput screening solutions.
Proteins are often, or can often be approximated to be, of globular shape, especially if the
ligand is bound to the protein. Under this assumption eq. 4.16 can be calculated analytically
[82]. We implemented and tested the electrostatic calculations based on this approach (details
see appendix A). To any protein complex we selected the sphere that approximates best the
electrostatic interactions of the protein cavity3 and calculated the electrostatic contributions
using this virtual sphere . As one can imagine this approach has problems for ligands, which
try to find a position outside of the cavity. We did not find a satisfying solution for such
cases.
If we neglect the solvent contribution for the electrostatic interactions between the bound
ligand and the protein, the resulting error is for buried ligands small enough to be neglected;
especially, if the resulting error is compared with inaccuracies that originate from the calcu-
lation of the partial charges by a standard force field. This is why at the moment we use a
standard Coulomb interaction (as in eq. 4.1.3) with a relative high dielectric constant.
In case of protein pockets with no or only very little contact to the bulk solvent, the de-
solvation energy of the protein is similar for all ligands that fill the cavity. For such cases it
is more important to calculate the solvation energy of the ligands than for the protein.
3For the optimization, we calculated for the charge distribution close to the cavity center, of a docked
native ligand and several surrounding sidechains, the solvation energies with the APBS program [8]. Then, by
changing the center and radius of a sphere we searched for the sphere which reproduces these results with the
least square deviation.
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For the ligands the analytical solution [82] that assumes a spherical or ellipsoidal shape of the
ligand is not applicable. By rewriting eq. 4.16, I want to introduce briefly the Coulomb field
approximation [140]
Eelec =
1
8pi²v
∫
<3
~D2dr+
1
8pi
(
1
²u
− 1
²v
)∫
U3
~D2dr. (4.17)
In eq. 4.17 the integral of the first addend is over the whole space (<3), whereas the integral
of the second addend is only over the volume of the solute (U3). In the Coulomb field
approximation it is assumed that the distortion field from the boundary ~Rreac(r), separating
two regions of different dielectric constant, can be neglected: The effect of the reaction field
is not taken into account.
~Di,v(r) =
qi
²v(r− ri)2
(r− ri)
|(r− ri)| +
~Rreac(r) (4.18)
This Coulomb field approximation can be applied to the first term of eq. 4.17 for the following
reason, because it can be shown that, at the integration outside the solute volume <3 \ U3,
~Rreac(r) contributes only very close to the solute and also because at the integration over the
solute volume, the distortion field is small compared to its influence in the second term, at
which the integration is over the same volume (if ²v À ²u).
Assuming that the partial charges are equally distributed on spheres with the atom radii Ri
and consequently avoiding the infinite energy self-contributions of the charges, Eelec can be
written to leading orders as [140]:
Eelec =
∑
i
 q
2
i
2²vRi
+
q2i
8pi
(
1
²u
− 1
²v
) ∫
U3\Vi
1
(r− ri)4dr
 (4.19)
+
∑
i>j
{
qiqj
2²vrij
+
qiqj
4pi
(
1
²u
− 1
²v
)∫
U3
~Di ~Djdr
}
, (4.20)
with U3 \ Vi being the whole space in the solute excluding only the volume of atom i with
radius Ri. Under this assumption the self-solvation energies per partial charge are slightly
overestimated. But the advantage of the approximation is that it can be easily calculated by
a numerical calculation over the solute volume.
The interaction part can not be simplified as easily. This is why we use an an empirical
approximation to calculate that contribution, which is provided with the generalized Born
approximation [157].
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Using this approximation the interaction energy of eq. 4.20 can be rewritten [139] to
Eint =
∑
i>j
{
qiqj
²urij
− qiqj
RGBij
}
, (4.21)
with RGBij =
r2ij +Reffi Reffj e −r
2
ij
4Reff
i
Reff
j

1
2
. (4.22)
Reffi , R
eff
j are effective atom radii; these depend on the shape of the molecule and are defined
by the generalized Born approximation [157]. As Scarsi et al. showed these effective radii can
be calculated by the results of the numerical integration of the first term in eq. 4.20. Being
aware of that the approximation works only well for smaller solutes, the total electrostatic
solvation energy of a ligand can be expressed as [139]
∆Belec,ligand =
∑
i
q2i
2
(
1
²u
− 1
²v
) 14pi
∫
U3\Vi
1
(r− ri)4dr−
1
Ri
−
∑
i>j
(
1
²u
− 1
²v
)
qiqj
RGBij
.
(4.23)
We implemented eq. 4.23 and we could very well reproduce the solvation energies of 400
randomly selected ligands from a larger molecule database. Our calculated solvation energies
are compared with those which were calculated using the program APBS [8] (see figure 4.5).
Solvation effects of the protein-complex are not considered in our studies, we present here.
Nevertheless in the newest program version we treat the solvation effects of the protein-
complex in the following way. We use a SASA-model that calculates the solvation free energies
as a linear sum of atomic contributions [37, 138]
∆B(r,Ω) =
∑
i
γgatype(i)Agatype(i)(r,Ω), (4.24)
with ga−type(i) 4.1.2 being the function that maps each atom to a defined atom-type. The
SASA-model does not take charges buried in the protein-ligand complex into account. This
is why this model underestimates the self-solvation energies of these charges. The model
has the advantage that it is quicker than any of the other presently methods used and still
has proven to be reasonably accurate [37]. It is widely used in biomolecular simulations
[37, 146]. Especially for our purpose it has the advantage that no pre-calculation of the
protein is necessary and ligands, which try to dock far outside of the cavity, are evaluated on
a reasonable footing.
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Figure 4.5: Comparison of numerical calculated solvation energies. Compared are the results
for the solvation energies of 400 ligands of the implemented routine, as in eq. 4.23, with
the very accurate numerical Poisson-Boltzmann solver APBS [8]. Due to optimizing the
correlation the atomic radii are decreased by 0.02nm. The correlation of the solvation energies
is with R = 0.986 very high. Our calculated values also do not have to be rescaled by a factor,
since they match already very well the numerical values.

Chapter 5
Docking Strategy
In this chapter, I introduce and describe the most important steps of the simulation process
(see figure 5.1). It is described how the ligand and the protein are represented in a simulation
and how their changeable dihedral angles are identified. At the end, I want to introduce one
of our new techniques which improves the simulation accuracy: Reasonable protein-ligand
conformations are pre-generated before the usual docking simulation starts.
Figure 5.1: Abstract process flow of a complete docking simulation for one ligand using our
approach
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5.1 Process Description
As Figure 5.1 indicates, the whole simulation process can be divided into two parts: Into
a ligand independent and a ligand dependent part. Already before any ligand structure is
investigated, the protein is analyzed by an automated procedure. All the parts of the protein
which do not alter during the simulation are pre-processed to ensure a quick evaluation of
the binding energies. For this purpose, position dependent Coulomb potentials and position
dependent atom neighbor lists are pre-calculated and stored on grids.
We allow some side chains, but not the backbone, to change their conformation. Side chain
flexibility can be assigned manually or by an automated procedure (see section 5.2). Treat-
ing side chains flexible during the simulation can be interpreted as the first approximation
of a completely flexible and thus as a realistic representation of the protein. The necessity
for flexible-protein docking has been widely discussed and recognized [24]. By including side
chain flexibility, many important protein deformations upon binding can be modeled.
Because the program optimizes the ligand as well as side chain conformations during a sim-
ulation, the final binding energy EBind depends on the energetic cost of the conformational
deformation of the ligand ∆EL,deform and the side chains ∆EP,deform:
EBind = ELP − EL − EP = ELP,inter +∆EL,deform +∆EP,deform. (5.1)
As a consequence, the relaxed conformations of ligand and side chains have to be determined
before the actual docking simulation can start. These conformations serve as an energetic
reference with which all other conformations are compared and with which ∆EL,deform and
∆EP,deform are calculated.
After the protein preparation, one or several ligands can be selected for a docking simulation.
The docking simulations are performed in the active site of the protein cavity. This position
has to be specified before the simulation can start. As a result, only side chains close to the
cavity and usually only the side chains which hinder ligands to bind or which improve the
ligand side chain interaction by a change of the side chain conformation should be selected as
flexible side chains.
The specified position of the protein cavity is also the starting point for our docking simula-
tion. For this purpose, an acceptable protein-ligand conformation initial of the simulation has
to be found. This initial protein-ligand conformation should be a ‘realistic’ conformation: i.e.
neighboring atoms should not overlap with each other1. Section 5.4 discusses the techniques
of finding initial protein-ligand starting conformation in more detail.
After the starting conformation has been found, the general docking simulation can start.
With the STUN-MC simulation we aim to find the global optimum of the PES. Different
docking strategies were compared but the cascaded docking procedure proved to be very ef-
fective as well as superior to a sequential procedure [107]. The cascaded docking procedure
1In our experience, it is very difficult to obtain meaningful docking results with a fixed number of computa-
tional steps if the docking simulation is started at conformations which are sterically forbidden. Due to Pauli
repulsion these conformations have an enormous binding energy in our force field.
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emerged as a compromise between the reduction of the statistical noise and the necessary
computational effort. As indicated in figure 5.1, the process is divided into three simulation
parts (stages). Starting with N1 independent docking simulations, their number is reduced
with each following stage: N1 > N2 > N3. In the cascaded docking procedure only the ener-
getically best simulations of the previous stage are continued. As the number of simulations
decreases, the computational effort spent on each stage increases. As a result of the cascaded
docking procedure, the statistical noise and also docking failures are reduced while limiting
the computational effort to an affordable amount [107]. Usually, we choose the Ni indepen-
dent simulation lengths for each stage in such a way that each stage uses approximately the
same computational effort in total.
During one STUN-MC step, either the conformation of the ligand or of one side chain is
altered. A conformational change of the ligand comprises, for example, a random translation
and rotation around the center of mass and additionally a change of one dihedral angle, if the
ligand is flexible.
At the end of stage 3, N3 results are returned. If N3 > 1, then the binding energies and the
different ligand conformations can be compared with each other. Such a comparison helps to
determine if the binding energies are reliable [44] and if the binding mode was unique.
5.2 Ligand representation
The ligands as well as the protein are represented classically (see chapter 4). In most protein-
ligand complexes, the ligand and the protein do not form any covalent bonds. Because of
this, an approach like ours that does not use quantum mechanical calculations can be applied
successfully.
Figure 5.2: Illustration of our ligand representation. As shown in the picture, we distinguish
different atom types (represented by different colors) and different covalent bonds (single or
double bonds). The molecular charge density of the molecule is approximated by assigning to
each nucleus a partial charge. The partial charges of the molecule are labeled in the picture
as an example.
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A full description of a ligand contains:
1. Partial charges for each atom
2. Van der Waals parameter for the atom type
3. Bonding topology
4. Bond type: σ, pi or σ-pi mixed bond
As we will see later (see the study in chapter 8), the better the description of the charge density
for the ligand and the protein the more reliable are the calculated electrostatic interactions
of the complex, and, as a consequence, also the docking accuracy.
5.2.1 Analysis of ligand flexibility
Unlike Molecular Dynamics (MD) simulations, our simulations do not allow bonds to be
stretched and to be squeezed. This is unnecessary, because we are not interested in the dy-
namics of the system but rather in the binding energy and in the resulting receptor-ligand
complex. Consequently, we fix the bond distances and bond angles (described as 1-3 inter-
actions in section 4.1.1) and allow changes of dihedral angles for the ligand and for the side
chain, (described as 1-4 interactions in section 4.1.1).
Through a statistical analysis of accurate small X-ray structures, Engh et al. [38] derived
parameters to refine less accurate X-ray structures. With the accurate structures they cre-
ated a parameter set for different atom types and showed that the measured bond lengths
and bond angles highly correlate with those calculated by the parameter set. The standard
deviations for the bond length and the bond angles are with 0.06 A˚ and 5 degree respectively
very small [38]. Consequently, in our program the ligand and the protein structure have to be
refined according to such parameters only once in the beginning. Afterwards, i.e. during the
docking simulation, it is not necessary to alter bond lengths or bond angles in order to refine
the structure. The deviations are so small that fixing the bond lengths and bond angles is
justified.
All bonds of the ligand are automatically investigated for possible flexibility. If a bond is
recognized as a σ-bond, then an energetic free rotation around that axis is allowed without
any torsional potential; restrictions arise only indirectly due to non-bonded interactions with
other ligand atoms (definition of non-bonded interactions see section 4.1.3). On the other
hand, if two atoms are connected by a pi-bond, we do not allow any rotation. QM calcula-
tions show that the participating electrons are de-localized between these bonded atoms and
that in relation to the dihedral angle often two low energy minima exist, which are separated
by high energies. The conformation corresponding to the two minima are referred to as the
cis- and the trans-orientation [96]. If such a bond is treated classically, a detailed analysis of
the rotational energies is necessary. Bonds which are partly pi- and σ-bonds are even more
complicated to describe with rotational potential energies.
5.3. Scoring function 49
Because of this, we presently do not allow rotations for these kinds of bonds.2
To identify pi-bonds we use the following rule:
First, we identify all carbons and nitrogen atoms which have 3 bonded neighbors as sp2-
hybrids. We consider all bonds which interconnect these sp2-hybrids as pi-bonds and do not
allow any rotation around these bonds. These rules also apply for the side chains. But
in addition to the automatic identification of pi-bonds, it is also possible to identify them
manually.
5.3 Scoring function
Many different scoring functions have been proposed in recent years [87, 174] but no clear
consensus has emerged to date on the superiority of force-field-based or knowledge-based
approaches. In our investigations, we employ a force field based scoring function originating
from physical principles:
S =
∑
i ²Ligand
∑
j ²Protein
(
ECoulij + E
LJ
ij + E
HB
ij
)
+Edeform.Lig. + E
deform.
P rot. (5.2)
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derived from the AutoDock scheme [114]. The scoring function of eq. 5.2 considers inter-
action energies as well as the deformational energies of protein and ligand. The interaction
energies between the protein and the ligand contains a term for the Coulomb interaction (see
eq. 5.3 and also section 4.1.3), a Lennard-Jones potential which combines the empirical Pauli
repulsion with the van der Waals attraction (see eq. 5.4 and also section 4.1.3) and a angular
dependent term which considers the interactions due to hydrogen bonds (see eq. 5.5 and
also section 4.1.3). As explained in section 5.1, the actual conformation of the protein and
the ligand are compared with their respective relaxed conformation; i.e. the conformation of
the protein or the ligand with the least internal energy. The internal energy itself is again
calculated with the Coulomb interaction energies of eq. 5.3 and the Lennard-Jones potential
2Another approach is to statistically evaluate the angular population for different bond types and to use
the frequency a specific dihedral angle appears to construct rotational potential energies. Programs like, for
example, Gold [73] use rotamer libraries of allowed and forbidden angles. In our approach we have not yet
included such libraries. We believe that, for example, the cis-trans conformational change should not be
done during the docking simulation, but before a docking run. Two different ligand conformations should be
generated (according to cis-trans) and used for separate docking simulations. Since a conformational change
from cis to trans is a large conformational change, it is unlikely that such a conformational change is accepted
by the STUN-MC criteria (see section 3.12).
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of eq. 5.4. We use the Lennard-Jones parameter σij of OPLSAA [75] as our established pa-
rameter set for most of our docking studies instead of the smaller AutoDock radii [114]; both
parameter sets as well as the parameters R˜ij and A˜ij of the hydrogen bond term are listed in
appendix C. We experimented with a number of other Lennard-Jones parameterizations and
found that binding modes depend to a large extend on the size of the radii. Using smaller
radii as, for example, in AutoDock increases the likelihood that the ligand will find a good
binding mode in validation studies, but will also increase the number of false positives in
screening applications.
We compute the partial charges (qi) for both receptor and ligand with the ESFF force field
[149] with the program InsightII [70] (at pH 7.4). This provides an adequate assignment of
the charges for both the protein and a wide variety of ligands: ESFF succeeded to automat-
ically assign consistent charges for over 180,000 ligands of the NCI Open database (210,000
ligands).
In previous studies, we found that a purely Coulomb-based representation of hydrogen bond-
ing significantly decreases the accuracy of the docking results, and we incorporated the hy-
drogen bond parameters R˜ij , A˜ij from AutoDock [114] as one established empirical model.
When specifically mentioned in the presented docking studies, we calculate the de-solvation
energies for the ligands with a term for the non-polar de-solvation energy (see section 4.2.1)
and for the electrostatic contribution to the de-solvation energy (see eq. 4.23) (atomic radii
are reduced by 0.02nm). The non-polar de-solvation energy is calculated with
Enon−polar = −30 cal
mol A˚2
SASAmolecule. (5.6)
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5.4 Methods for generating an initial protein-ligand confor-
mation
In our approach several independent docking simulations are performed for each ligand. Each
simulation starts from a different initial protein-ligand conformation. As discussed in section
5.1, it is advantageous to use such an initial conformation which corresponds to an energy
below a defined limit. This energy is calculated by our scoring function. As a consequence for
the energetic limit of the conformation, initial protein-ligand conformations with minor atom
penetrations are allowed, whereas those with a larger overlap between atoms are forbidden.
Several strategies to find these allowed protein-ligand conformations are implemented and
used:
1. Using the relaxed ligand conformation and placing it by random translation and rotation
in the cavity until an allowed protein-ligand conformation has been found.
2. Same as point 1, but with three different ligand conformations: Conformations resulting
after a small stochastic optimization to find the conformation of lowest energetic energy
(relaxed), of largest end to end distance (straightened), and of smallest radius of gyration
(globular).
The downside of these methods is that they all assume a spacious cavity. If the cavity is
narrow, then it is left to chance, if one of the ligand conformations (relaxed, straightened or
globular) can be fitted into the cavity by mere translations and rotations. Figure 5.3 displays
a two dimensional representation of such a difficult case. The ligand fits tightly into the
protein cavity, which is represented by dashes. If the ligand conformation is very different
from the one which is displayed, it is not possible to find an allowed conformation by mere
translations and rotations of the whole molecule.
Figure 5.3: Ligand and cavity representation in 2 dimensions. The border line of the cavity
is plotted by dashes. As illustrated, the ligand fits tightly into the cavity.
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Figure 5.4: Receptor-ligand complex (pdb: 1STC); on the left picture the ligand is shown in
the cavity of the receptor (grey); on the right picture the receptor structure is replaced by
attractors, which constitute an attractor field (the view angle is changed by about 180◦)
This is one of the reasons why we decided to implement a pre-docking method using very
small MC simulations, even though MC simulations and optimizations are difficult and time
consuming, when many local energy minima at the PES are between very high energies. To
avoid these problems a different protein representation is used to find allowed protein-ligand
conformations.
The purpose of the pre-optimization routine is to find ligand conformations in allowed regions.
The ligand should have already adapted to the protein structure, before the usual docking
routine starts. Since our aim is to dock many ligands in a short period of time, it is necessary
that the pre-optimization routine is very quick.
Therefore, in a first step the empty space (discretized by a grid) of the protein is calculated.
All grid points which are further away to any protein atom than the radius of the protein
atom and of an additional atom which corresponds to a potential ligand atom are considered
as points of the empty space. Since we are not interested in protein-ligand conformations
that do not interact with each other, we restrict the empty space. If the grid points which
correspond to the empty space are further away than 5 A˚, then these points are neglected as
being too far away from the protein.
The two different representations are shown in figure 5.4. The left picture displays a closeup
of the cavity and the docked ligand staurosporine (PDB: 1STC). The empty space the ligand
can accommodate in is replaced by grid points, attractors, which are illustrated in the right
picture of figure 5.4.
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After the empty space is calculated, in a second step, an attraction field is calculated that
evaluates each atom of a ligand conformation in the cavity according to the distance to the
next attractor, the grid point of the empty space. Thus, in the attraction field a protein-ligand
conformation is calculated by
Eattraction =
∑
i ² atoms
B min(∆ri,attractor), (5.7)
with the constant energy factor B and the distance to the closest attractor min(∆ri,attractor).
Refining a conformation on this attractor-PES usually takes less than one CPU second. This
enables us to refine and compare a high amount of different ligand conformations with each
other.
Hydrogen bonding is important for the stabilization of a protein-ligand conformation. Possi-
ble hydrogen bond donors or attractors of the ligand should be saturated as much as possible.
Under this assumption we added another criterion to identify among the allowed conforma-
tions further good or bad protein-ligand conformations. Each possible ligand hydrogen bond
attractor or donor should be in the usual hydrogen bond distance (2.8 A˚ [86]) to the partic-
ipating partner. Therefore, the least distance from a ligand donor or attractor to a protein
atom partner is calculated and is energetically evaluated in a similar way as in eq. 5.7, if
this least distance exceeds the 2.8 A˚ hydrogen bond distance (not the smallest distance is
evaluated, but the difference in distance to the usual hydrogen bond distance). Both energy
contributions are added together to constitute the attractor-H-PES.
All together a total Pre-docking simulation consists of:
1. Generation of at least 500 energetically allowed different ligand conformations (rotations
around as many bonds as possible)
2. Search for the two best ligand orientations of each of the 500 conformations in the
attractor-H-PES field (the ligand is rigidly rotated around a defined cavity center by
step sizes of 30 degrees)
3. Conformation refinement of the energetically best N1 conformations in the attractor-
H-PES (For this purpose, we use the SA optimization technique, to ensure a quick
optimization on the not very complicated attractor-H-PES)
4. If necessary, the conformation is briefly refined in the atomistic protein structure ac-
cording to our scoring function.
After these 4 steps, the protein-ligand conformation is ready for a STUN-MC docking sim-
ulation. In total, the whole conformation generation and optimization takes less than 20
seconds on a modern CPU. The advantage of this method is that a by far larger ligand
conformational space can be sampled which makes the docking simulation independent of
conformations loaded from files.
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It is obvious that the pre-optimization is superior to the previous methods if the cavity
is very narrow and has a non-isospheric shape. In addition, however we analyzed the binding
accuracy of wider cavities with the attractor-H-PES optimization. To test the behavior of
our routine, we docked 10000 ligands of a randomly generated database to a homology model
of the methyl transferase receptor and compared the calculated binding energies with and
without pre-optimization. Methyl transferase methylates the deoxyribonucleic acid. These
proteins are involved in the carcinogenesis in humans and presently it is investigated if the
methylation process can be influenced by inhibiting the catalytic site of the enzyme with
small compounds [102].
Binding Energy (kJ/mol) without pre-optim. with pre-optim.
(-230.0, -190.0] 1.0 1.0
(-190.0, -150.0] 21.0 27.0
(-150.0, -110.0] 387.0 410.0
(-110.0, -70.0] 2389.0 2466.0
(-70.0, -30.0] 4097.0 3803.0
(-30.0, 10.0] 1162.0 1173.0
(10.0, 50.0] 456.0 508.0
(50.0, 90] 253.0 306.0
Table 5.1: Comparison of the docking results with and without the pre-optimization method.
It is being compared how many ligands were found at the different binding energy intervals
(up to 90 kJ/mol).
The results, listed in table 5.1, show that by using the pre-optimization method, more ligands
found an energetically top-ranking position than without. This behavior remains the same for
structures ranking better than the binding energy of -70kJ/mol. The optimization method
proved to be useful for the top 13 ranking ligands of the database.
At the interval from -70 to -30 kJ/mol, not using the pre-optimization method seems to work
better. Most of the 10000 ligands have a binding energy in this energy interval. These ligands
fit into the receptor but they do not have a very stable binding mode.
At the moment the pre-optimization routine can generate very similar protein-ligand confor-
mations as starting points for the STUN-MC docking simulation. In case of good binding
ligands, the pre-optimization proves to work successfully in selecting good initial conforma-
tions. But in spacious cavities, as for the protein methyl transferase, it is disadvantageous, if
the initial protein-ligand conformations are too similar. Including diversity rules, which force
a higher diversity for the initial conformations, may further improve the docking accuracy.
Chapter 6
Binding Accuracy Evaluation
The reliability to determine the native binding mode is an important test for both the scor-
ing function and the search method in protein-ligand docking. Only if the scoring function
describes the protein-ligand interactions well, the native protein-ligand conformation can be
identified by the best score. On the other hand, a suitable method must be implemented to
find this particular protein-ligand conformation reproducibly.
In this chapter, we investigate, how well FlexScreen can predict experimental binding modes
with a simple interaction-based scoring function, solvation effects are excluded. For this
test, we perform docking simulations with eighty-three protein-ligand complexes of the high-
resolution subset of the ASTEX/CCDC protein-ligand data set.
6.1 Introduction
As the number of therapeutic targets with available structural information increases, virtual
screening of chemical databases to targets of known three-dimensional structure is developing
into an increasingly reliable method for in-silico drug development [2, 36, 85, 160, 173]. Both
better scoring functions [13, 154, 87] and novel docking strategies [1, 10, 21, 56, 93, 103, 143]
contribute to this trend, although no completely satisfying approach has been established
yet[13, 174]. The complexity of the physical principles governing protein-ligand interac-
tions makes the formulation of simple, numerically tractable representations a daunting
task [147]. It is presently controversial whether force field-based scoring functions based
on biochemical/biophysical models are capable to adequately represent the complex interac-
tions that stabilize ligand-protein complexes or whether knowledge-based scoring functions
[14, 33, 55, 64, 67, 166, 79, 112, 115, 165] offer more promising results. Techniques, which
parameterize protein-ligand interactions without explicit reference to the underlying phys-
ical interactions, promise to capture even those contributions to the interactions that are
not easily accounted for by numerically tractable physical parameterizations. Such effects
include the formation of hydrogen bonds [16], polarizability and the complex influence of the
solvent [77]. The virtue of a simple implicit representation of these complex phenomena in
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terms of potentials of mean force spurred the development of many regression-based scoring
functions. Increasing computational power has permitted these techniques to adopt atomistic
representations [50] of the protein-ligand complex. Partially because of their higher cost, force
field-based scoring function have received much less attention [13, 174, 79]. The feasibility of
direct atomistic simulations of the docking process through molecular dynamics [9, 127, 76]
offers an increased ability to parameterize and validate force field-based scoring functions
on individual protein-ligand complexes. Force field-based scoring functions, which explicitly
refer to established modes of interaction, have been argued to offer better transferability and
extendability. In addition, the key-lock-principle, crucial for protein selectivity and problems
of induced fit [28, 117], is obviously well represented in a framework that treats the protein
and all ligands on the same footing. In this study we have investigated an atomistic docking
approach, using a very simple force-field-based scoring function, which is very similar to that
used by AutoDock [114], with respect to its accuracy for binding mode prediction. The accu-
racy by which experimentally resolved ligand-protein complexes are reproduced, serves as one
important measure to assess the reliability of in-silico screening approaches. Regression-based
methods have demonstrated an impressive progress over recent years [150, 79]. This improve-
ment stems undoubtedly from the improved performance of both the docking methods and
the underlying scoring functions.
6.2 Methods
There are two major ingredients to an all-atom in-silico screening method: (1) a scoring func-
tion that approximates the binding energy (ideally the affinity) of the protein-ligand complex
for different possible conformations of the complex and (2) an efficient optimization method
that is able to locate the binding mode of a given ligand to the protein as the global optimum
of the scoring function. In a database screen, all ligands are assigned a score, which ideally
approximates the affinity of the protein-ligand complex on the basis of the predicted binding
mode. Promising lead candidates are then identified by ranking the ligands in the database
according to their score. Methods that fail to predict the correct binding modes of known
protein-ligand complexes can give fortuitous results in large-database screens. The prediction
of the correct binding modes thus emerges as a necessary, but not as a sufficient criterion
for in-silico docking protocols. Limitations in the available computational resources and the
large number of possible ligands enforce severe approximations in the representation of pro-
teins and ligands. Further difficulties arise from the complexity of the interactions governing
protein-ligand interactions. In this study we employ a comparatively simple, interaction-
based scoring function and use a fully automated docking protocol, including receptor and
ligand preparation.
The number of possible protein-ligand hydrogen bonds is constrained [171, 172] for each hy-
drogen bond donor or acceptor in ligand and protein to ensure only the evaluation of physically
possible interactions. Omission of such constraints leads to unphysical binding conformations
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Figure 6.1: Resulting optimal protein-ligand conformation of 1LIC, when the scoring function
does not account for the number of hydrogen bonds formed by each atom. The SO3-head
group of the ligand forms 3 hydrogen bonds to a single H-bond donor, leading to un-physically
high stabilization energies for a conformation which differs from the X-ray conformation by
4.27 A˚. If the hydrogen bond counting is enabled, as described in the methods section, the
energetically lowest binding mode improved to 1.08 A˚ RMSD. In this figure, as well as the
following illustrations of protein-ligand complexes, the protein pocket is represented as a gray
cavity and atoms are color coded, highlighting specific groups of interest.
as illustrated in figure 6.1. We note that crystal water and co-ligands, such as conserved ions,
are easily implemented in the model by treating them on the same footing as rigid protein
atoms.
6.2.1 Docking Protocol
The docking simulations were performed using a cascaded docking approach (see section 5.1):
The total number of simulation steps is divided into several partitions of similar computational
effort. To obtain good statistics we chose a protocol that results in ten final conformations for
each protein-ligand complex: In the first partition of the simulation a large number (1000) of
short simulations (5000 steps per run) is performed on the ligand. The 50 trajectories with
lowest binding energies are then continued for additional 30000 simulation steps each. Of the
resulting conformations, again only the lowest ten are selected and further optimized using
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another 75000 steps. Each step comprises a random rotation of the ligand, a translation of its
center of mass and rotations of each of its flexible bonds, the new conformation is accepted
or rejected according to the Metropolis criterion based on the effective energy of the scoring
function (see section 3.2.2). This protocol generates ten nearly independent conformations
for each protein-ligand complex with a total of 725000 energy evaluations. Depending on the
number of ligand atoms (and hence interactions) one such simulation requires 2-3 minutes
of cpu-time (on Intel Xeon 2.4 GHz). The cascaded docking strategy balances diversity and
computational effort. It invests the largest computational effort into the most promising
candidates at the end of each partition, while unsuccessful simulations are terminated early.
The difference in the scoring function for the final conformations can be used as a posterior
error estimate and serves as an indication whether the predicted binding mode is unique.
6.3 Receptor Structures
The protein-ligand complexes were taken from the Astex/CCDC validation set [123]. We
concentrated on the subset of highest quality, containing 92 structures with a resolution of
better than 2.0 A˚. The protein conformations in the data set (including hydrogen atoms
and to some extent partial charges) were frequently insufficient to implement our all-atom
scoring function. In many cases, only the neighborhood of the docking site was explicitly
included in the data set. For reasons of consistency we therefore prepared the entire set of
protein structures on the basis of the original entries of the PDB database using InsightII [70].
This procedure has also been our standard for the screening applications reported previously
[107, 106, 108]. Starting with the de-protonated protein structure, hydrogen atoms were
attached using the InsightII Builder module, choosing protonation states on the basis of a
physiological pH value of 7.4. Partial charges were then assigned with the universal all-atom
force field ESFF [149]. In contrast to other studies [73, 50] no pre-optimization of the initial
protein or ligand structures were performed, as these tend to adapt the protein pocket to the
desired binding mode and hence bias the investigation. Unless explicitly noted below, all the
water molecules present in the PDB structures were removed.
6.4 Results
Nine of the 92 ligand-protein complexes were omitted from the investigation because either
these ligands were covalently bound to the protein (1aec, 1b59, 1tpp, 1vgc and 4est), or the
ligand coordinated with a metal center (2h4n, 1lna, 1xie) or because there were no direct
interactions between ligand and protein (3cla). Since the interactions to treat these cases are
not implemented in the scoring function used in this investigation, results obtained for these
complexes would be fortuitous. The table B.1 (see appendix) demonstrate the overall accu-
racy obtained for the binding modi of the high-quality Astex data set using the FlexScreen
flexible-ligand screening approach described above. We list the (median) RMS deviations of
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Figure 6.2: Histogram of the RMS deviations for all investigated protein ligand complexes.
Only 8 simulations resulted in RMS deviations larger than 5 A˚.
the ten final conformations with respect to the X-ray structures, the (root mean) fluctuations
of the binding energies and the RMSD obtained with Glide [50], Gold [73] and FlexX [134]
(as cited in [50]), where available. The data show that 68 of the 83 complexes (81.9%) are
predicted within a median root mean square deviation (RMSD) of less than 2 A˚. The distri-
bution of RMS deviations for all runs (10 per ligand) and all ligands is shown in figure 6.2.
This compares to 57.1%, 76.0% and 71.4% for FlexX, Gold and Glide respectively. Applying
a threshold of 1 A˚, FlexScreen predicts 50 complexes within a RMSD of 1 A˚ (60.2%). This
compares to 23.2%, 44.0% and 51.8% for FlexX, Gold and Glide respectively. Averaged over
all complexes the median RMS deviation to the experimental binding mode was an impressive
0.83 A˚, and the unique native binding mode was found in 61 of the 68 cases, indicating the
reliability of the docking protocol. An example for an ideal docking result is shown in the
left side of figure 6.3, which illustrates the overlay of the 10 docked conformations (thin) in
comparison with the experimental conformation (thick). In such cases where not all simu-
lations found the same binding mode (see the right side of figure 6.3 for an example), the
one binding mode to be regarded as the natural conformation was selected according to the
lowest computed binding energy (this is the case in 7 complexes).
There are eleven protein ligand complexes where the FlexScreen protocol fails to locate the
correct binding mode, one example is illustrated in figure 6.4, where a very open binding
pocket leads to many badly docked conformations. A correct prediction of the binding mode
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Figure 6.3: Illustration of the computed and experimental binding mode of 1hls and 1hsi.
In the first case all of the ten independent simulations correctly identified the experimental
binding pose, in the second example two of ten simulations found different binding modes,
which are higher in energy.
of this complex requires the treatment of additional entropic contributions and possibly the
inclusion of de-solvation effects in the scoring function These data demonstrate that experi-
Figure 6.4: Predicted and experimental binding modes of 1bma: the scoring function fails to
identify the correct binding mode in a comparatively open binding pocket. This difficulty can
be traced back to the scoring function, because the correct binding mode is also sampled, but
misplaced conformations repeatedly score with better binding energy.
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mental binding modes are very well reproduced for the majority of ligand-protein complexes
in the data set. However, there are a few notable and characteristic difficulties that are also
likely to be encountered in practical screening applications. In the following, we will discuss
these difficulties in detail to illustrate how an atomistic interaction-based scoring approach
can lead to rational improvement.
6.4.1 Steric Hindrance
If there are clashes between the ligand and the protein in the experimental X-ray struc-
ture, this binding mode is unattainable in the docking approach. In this study, 3 complexes
(1tni, 1tnl and 1eta) showed such clashes. In 1tni and 1tnl, hydrogen pairs between protein
(GLY216) and ligand exist in the experimental conformation, which have a distance of 1.50
or 1.79 A˚. Such distances are too short for most accurate all-atom force fields which assume
an equilibrium distance of at least 2 A˚. We have used the full vdW radii of the OPLSAA
potential for the docking simulations, which generates clashing experimental conformations
for such protein-ligand complexes. We applied this approach here nevertheless for consistency,
because it reduces the number of false positives in screening applications. In the past, two
methods were suggested to remove these clashes for binding mode predictions:
In the investigation of Glide [50], such problems were largely eliminated by annealing away
initial clashes. Even the positions of heavy atoms of the protein were optimized in the pres-
ence of the ligand under the condition that the RMS deviation of the complex remained below
0.3A˚. This procedure improves the docking accuracy for the particular protein-ligand complex
under investigation, but it cannot be generalized to screening applications, where the ligand
binding mode is unknown. Annealing only the side chains of the cavity before docking also
helped to eliminate the clashes in our simulations.
As an alternative approach to the problem of clashing conformations, we repeated the docking
simulations with the smaller radii used by AutoDock. Then, all of the ligands enumerated
above docked with median RMS deviations below 2 A˚. We believe that the use of artificially
small radii is preferable to the use of annealed structures, because it can also be applied, when
no ligand-protein structure is available. We also note that many clashes occurring in rigid
protein screens can be avoided at moderate computational cost by using a flexible protein
screening tool, such as FlexScreen. To illustrate this point we have performed flexible protein
screens for 1xid, where only one of the ten trajectories reached a conformation within 2 A˚
to the experimental binding mode. Even though this conformation had the lowest energy,
the median RMS deviation was 3.22 A˚ and the energies of the metastable competitors to the
experimental docking mode were very close to the optimum. Using a flexible protein screen
(4 protein degrees of freedom for the dihedral rotations of the amino acids: GLU 181 (2),
ASP 287 (1) and LYS 289 (1)), nine of ten trajectories reached the experimental binding
mode, which reduced the median RMS deviation to 0.9 A˚ for this system. In the flexible
protein screen the energy difference between the metastable and the near-experimental con-
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formations also increased substantially, indicating that the true experimental minimum was
not accessible in the search space of the rigid protein. The principal advantage of this method
is that the same protein degrees of freedom can be made flexible without bias during database
screens, thereby treating all database ligands on the same footing.
6.4.2 Presence of water and small ions
The treatment of conserved water molecules and small ions is an important outstanding
problem in atomistic docking models [95](see figure 6.5). Removal of these molecules increases
the size of the cavity, leading to potentially incorrect results, while their explicit treatment
would increase the size of the search space drastically and place high demands on the accuracy
of the scoring function. A dramatic illustration of the influence of crystal water is 3cla, where
the ligand is almost entirely embedded in water. Various water molecules are located in the
neighborhood of the ligand to stabilize the binding mode. Although some scoring functions
(e.g. Glide [50], AutoDock [126]) implicitly account for solvation effects, this approach remains
fruitless here, because the water molecules serve as bridges that mediate the ligand-target
interaction. We note that none of the docking programs was able to predict a protein-ligand
conformation within a RMSD < 2.0 A˚ for this complex. The determination of the correct
binding mode is only possible with an explicit placement of water. Using FlexScreen, this
modification led to an improvement of the RMS deviation from 5.9 A˚ to 0.93 A˚. There are also
examples (1atl, 1jap, 1xie, 1slt, 1lna) where the ligand appears to form no hydrogen bridges
with water, but where conserved water molecules occupy and effectively block remote parts
Figure 6.5: Ligand-protein complexes that are stabilized by crystal water. In the case of
3cla (left) the ligand is stabilized by a network of conserved water molecules that mediate
indirect interactions between ligand and protein. For 1lna (right), water molecules bound to
a calcium ion occupy parts of the protein pocket and confine the ligand to its experimental
position. Even though there are no direct stabilizing interactions between ligand and these
water molecules, their omission leads to the prediction of a wrong binding mode.
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of the cavity. If these are removed, the ligand may find binding modes which were initially
excluded and are now competing with the correct binding mode. These complexes provide
suitable examples for the development of solvation models, which must take into account the
affinity contribution of water molecules interacting with vacant parts of the target.
6.4.3 Comparison with AutoDock
To put these results into perspective, we must ask whether the good performance results
primarily from the superiority of the scoring function or from the accuracy of the docking
method. This issue can be resolved by a comparison of the FlexScreen results with those
of AutoDock, in particular for closed protein pockets where solvent interactions have little
differential effect on the docking position. Unfortunately, there is no AutoDock data available
for the entire CCDC/ASTEX data set. In table B.2 (see appendix) we summarize data from
a recent comparative investigation that reported AutoDock data for 11 complexes of this
set. In addition we succeeded to generate data for another 14 complexes in independent
investigations (2 complexes are same). This data is also included in table B.2. Comparing
these results, we see that FlexScreen / AutoDock predict the correct binding pose to within
1 A˚ RMSD in 13 (52%) / 4 (20%) of the cases respectively. Reducing the criteria to 2 A˚, we
find success rates of 18 (72%) / 14 (56%) respectively. Comparing the data on a case-by-case
basis, we see that FlexScreen yields more accurate binding poses in 16 (64%) of the cases.
6.5 Discussion
We have investigated the accuracy of the predicted ligand-protein conformation for 83 com-
plexes of the high resolution ASTEX/CCDC data set, for which crystal structures with an
experimental accuracy of better than 2 A˚ are available. For each system we obtained 10 con-
formations for the protein-ligand complex using FlexScreen, which performs atomistic docking
simulations based on the stochastic tunneling method with a simple, interaction-based scoring
function. The median RMS deviation between the predicted and the experimental structure
is 0.83 A˚. Each of the ten simulations per ligand performed here requires between 2-3 minutes
of CPU time on standard off-the-shelf hardware.
We have compared the accuracy and success rate, defined as the fraction of ligands that were
docked in a position with a median RMS <2.0 A˚, of FlexScreen with other docking methods
(Glide, Gold and FlexX), which have been tested for the same data set [50]. In over 80%
of the cases, FlexScreen found a binding mode with a RMS deviation of less than 2.0 A˚ ,
compared with 57%, 71% and 76% for FlexX, Glide and Gold respectively. In a case-by-case
comparison for each of the complexes, FlexScreen achieved a lower median RMS than the
values reported for FlexX, Gold and Glide in 79%, 72% and 46% of the cases, respectively.
In contrast to the investigation of Glide, no annealing of the complex prior to docking was
performed. FlexScreen succeeded to find binding modi in some of the sterically difficult cases.
FlexScreen approximates the computationally more involved MD based docking schemes [181]
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and achieves similar accuracy for many of the targets investigated here. Where affinity differ-
ences of a few kJ/mol matter, the exploitation of relevant protein degrees of freedom may be
of importance to obtain optimal hydrogen bonding. These observations correlate well with
results for other MC/MD based docking methods [168], where MC/MD based docking meth-
ods outperformed GA based search strategies for large search spaces and complex docking
problems. While GA based techniques are very efficient to explore conformational spaces
with uncorrelated degrees of freedom, they may have difficulties to search spaces in which
intramolecular rearrangement must correlate with the center-of-mass motion to find the op-
timal docking mode. We also note that with force field-based scoring functions, widening of
the pocket with soft LJ potentials may reduce selectivity [167]. In our approach, interme-
diate clashes are avoided by the STUN transformation, so that the full potential may be used.
Overall, these results demonstrate that a cascaded all-atom docking protocol with a simple
force field-based scoring functions can yield very accurate results that match or exceed those
of recently developed knowledge-based models. Our comparison with AutoDock suggests that
the reliability of the screening protocol is crucial to obtain these results. As expected for many
of the closed binding pockets of the present test set, the scoring function as such appears to
be less relevant, as long as minimal accuracy requirements are met.
We stress that results obtained for binding modes are not necessarily transferable to screening
applications where the rank order of different ligands in the correct binding pose ultimately
determines success. The scoring function has obvious limitations for lipophilic interactions
and the ranking of affinities with large differential solvation effects.
Much work remains to be done, regarding both the parameterization of scoring function
and docking methodology, to make force field-based methods universally applicable. The
treatment of metal-centers in classical potentials will require knowledge-based components
in the scoring function. The treatment of crystal water mediating a hydrogen bond network
of the ligand, as well as that of other mobile ions, remains a significant challenge in screen-
ing applications where the existence and position of such co-ligands cannot be controlled on
a case-by-case basis. Our approach delivered good results only when these molecules were
properly accounted for. Since the search space of the docking program increases rapidly in
the presence of such molecules, thermodynamics-based search methods, such as simulated
annealing, genetic algorithms or stochastic tunneling, may be the best option to tackle such
complex problems.
Chapter 7
Importance of Protein Flexibility
In this chapter, we investigate both benefits and present limitations of the treatment of
target flexibility for high-throughput in-silico database screenings. Among the benefits are an
improved diversity of binding modes, which allows to identify a wider class of drug candidates.
The limitations are related to a diminishing docking accuracy and an increased number of
false positives.
7.1 Introduction
The key-lock principle, primarily focused only on geometric criteria [45], is the starting point
for rational drug design: if either one ligand of the enzymatic process is known, or the X-
ray crystallographic structure of a binding site of the protein has been determined, then a
blueprint of a potential drug candidate, a pharmacophore model, can be constructed and
molecules designed that share a certain similarity with that blueprint. This strategy has been
applied during the last two decades in many successful drug design projects [31].
Difficulties arise, if the conformation of the protein structure depends on the type of ligand,
that binds to the protein. As one can imagine, different possible protein conformations permit
a far more diverse set of ligands to dock well to the protein.
7.2 Method: Flexible docking to Thymidine Kinase
The following docking simulations were performed using the thymidine kinase (TK) enzyme as
an example of a flexible protein. This enzyme has since long been in focus of pharmaceutical
research because of its role in reproduction of the herpes simplex virus [34]. It has since then
emerged as a useful benchmark system in rational drug design, because not just one, but
ten active inhibitors are known and the X-ray structures of their binding modes have been
identified [13]. When these ten inhibitors are mixed with a database of randomly selected
compounds, the screening tool should be able to identify these as being good binding ligands,
i.e. it should assign a high rank to these benchmark ligands. The present enzyme structure is
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of particular interest, since the measured target conformations of the various complexes are
significantly different.
7.2.1 Preparation of the ligands and the docking site
First, 10000 compounds were randomly chosen from the open NCI database[111]. Since,
at this stage, no partial charges were assigned to these compounds, we used the Insight II
package [70] with ESFF force field[149] and an automated script to evaluate partial charges
for each ligand atom at ph 7.4.
For our analysis, the ligand-free X-ray TK enzyme structure (1e2h)[170]) was taken from the
PDB database, partial charges were assigned using Insight II. The ligand-free structure was
chosen in order to avoid any conformational bias, created by the ligand closely interacting
with flexible side chains inside the binding pocket.
7.3 Results
7.3.1 Screen using a rigid enzyme structure
The database screen was carried out using the cascaded docking method (see sec. 5.1):
we start with a population of 100 different conformations, for which we do short docking
simulations with 7500 steps. The energetic best five conformations are selected for further
Inhibitor rigid 6 flex 6 flex+SO4
acv 221 55 38
ahiu 1454 1315 794
dhbt 2 2 1
dt 308 172 45
hmtt 3117 2934 2076
hpt 8 13 7
idu 612 97 23
mct nd 4180 4054
pcv 437 71 25
gcv 187 14 4
Score 5225 6576 7063
Table 7.1: Comparisons of different database screens. For each screen we compare the rank
of the TK inhibitors in a screen with 10000 randomly chosen ligands of the NCI database.
Finally, we evaluate each screen with a score that quantifies how well the active compounds
are identified as high affinity ligands. The top row designates the docking model that was
used in the screen (nd = not docked)
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Figure 7.1: Histogram of the resulting ligand binding energies after a screen to the TK enzyme
[pdb code: 1E2H] (positions of the known inhibitors are highlighted). Left: Screen to the
rigid ligand-free enzyme structure. Right: Screen using a flexible target.
simulations on the next stage with 30000 simulation steps each. Finally the two best energetic
conformations are again refined with 75000 simulation steps. In this screen, 3291 database lig-
ands attained a stable conformation with negative binding affinity within the enzyme pocket.
The resulting ranks for the ten inhibitors during this screen are summarized in table 7.1
(second column). The ligand dhbt and hpt were ranked with a very high affinity. The ligand
hmtt and mct docked badly. Hmtt has barely reached a negative binding energy, whereas
mct has never been bound. The majority of the benchmark ligands were energetically more
or less close to each other but did not score especially well, as one may notice in the left panel
of figure 7.1.
Repeating the docking simulations for these ligands did not substantially improve their rank
in the database, eliminating the possibility of statistical fluctuations of the docking algorithm
as the source for this difficulty. This enrichment rate is comparable to the results of other
scoring functions that were previously investigated for this system, but the overall perfor-
mance is quite disappointing [13].
In a previous study [44] we compared different database screens to different rigid enzyme
structures. In these cases a high specificity of the enzyme to its complexed ligands could be
observed. Only those ligands scored well which were similar in their structure to the ligand,
the enzyme formed the complex with. This ‘memory effect’ is a straight consequence of the
key-lock principle. Such a high degree of selectivity is spurious, however, since the natural
receptor or enzyme, the ‘lock’, contains a certain degree of flexibility to accommodate a vari-
ety of ligand structures ‘keys’. The rigidity of the model is thus causing a lack of diversity of
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the screen, and consequently the majority of potentially good drug candidates are rejected in
such a simulation. The introduction of target degrees of freedom delivers an important tool
to recover the diversity of the screening method.
7.3.2 Identification of important side chains
It is immediately clear that a relaxation of all side chains which are located near the binding
site is not feasible with todays computational resources, a consequence of the combinatorial
explosion of the conformational space. Instead, those side chains which would play an impor-
tant role in the binding modes have to be identified and partially released.
For this particular pre-study, the X-ray structure of TK in complex with the ligand hmtt [182]
was used. The side chain GLN125 was quickly identified as an important hot spot for the
binding motif, forming two hydrogen bonds with hmtt. When comparing different complexed
crystal structures of the same enzyme with each other, GLN125 turned out to be highly
flexible: Its conformation was significantly changed with the ligand it was interacting with.
To simulate such a system, 3 chemical bonds of GLN125 (among others) were made flexible
to allow the ligands to find their individual binding motifs. The figures 7.2 show two final
conformations of a docking simulation for the two ligands dt (left) and gcv (right). Similar to
the measured X-ray structures, in our docking study the side chain GLN125 has changed its
conformation as well. Dt, utilizing the same binding mode as hmtt, did not modify the side
chain orientation significantly compared to the X-ray side chain orientation. On the other
hand, when gcv was docked into our flexible enzyme structure, the side chain was moved to
Figure 7.2: The X-ray structure (grey) along with the simulated conformation of GLN125 and
the docked ligand. Left: dt (deoxythymidine) docked into 1e2n. The side chain movement is
insignificant, since the binding pattern of this side chain matches to this ligand. Right: gcv
(ganciclovir) is docked to 1e2n. Since the original crystal binding motif of GLN125 did not
allow the ligand to form its individual interaction pattern, a new side chain conformation was
energetically more favorable
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Figure 7.3: Histogram of the changeable three dihedral angles of GLN125. For 640 final
conformations the number of occurrences for each dihedral is plotted
form the two important hydrogen bonds with the ligand, as can be seen in the right figure.
In the following, we analyze the dihedral angle population of the side chain GLN125 for the
final enzyme-ligand conformations after a docking run of the 10 known active substances [13].
For each of the active compounds 32 independent simulations were performed, and those two
conformations with lowest energies were selected for the analysis. The conformation of side
chain GLN125 can be represented by the three dihedral angles Φ1, Φ2 and Φ3. For each
dihedral angle the number of occurrences at the different angles is plotted in the histogram
of figure 7.3. The histogram shows more than just three peaks for the different dihedrals: Φ1
and Φ2 form two separate peaks, but the dihedral distribution of Φ3 separates into two heaps.
In order to allow the two ligands, as illustrated in figure 7.2, their individual binding modes,
this side chain had to flip around by 180 degree, as also observed in the crystal structures.
In a similar manner, other side chains whose flexibility would contribute to increase the di-
versity of the database screen could be identified. For the following screen, 4 side chains with
a total of 6 degrees of freedom were introduced into the structure 1e2h, namely dihedral ro-
tations of the amino acids GLN125(3), TYR101(1), ARG222(1), and HIS58(1) (the numbers
in brackets denote the respective numbers of flexible bonds).
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Binding mode analysis
In the following we want to mention problems, that are caused by crystal water, which are also
present in the cavity of TK. Analyzing the binding modes of the ten active compounds in the
cross-docking simulation (averaged over 32 conformations each), six out of the 10 compounds
find a binding mode with less than 2 A˚ RMSD (root mean square deviation of non hydrogen
atoms) to its complexed structure. These results are listed in table 7.2. Three of the four
Inhibitor acv ahiu dhbt dt gcv hmtt hpt idu mct pcv
RMSD/A˚ 3.55 3.29 1.28 0.5 0.88 1.02 2.76 0.79 3.37 1.37
Table 7.2: Averaged cross docking results for the ten active compounds. The RMSD is
measured to the specific ligand in its complexed X-ray structure which was aligned to 1e2n.
wrongly docking ligands (ahiu, hpt and mct) have in relation to the side chain GLN125 a
symmetric binding pattern: the interaction between these ligand and GLN125 (the main side
chain for hydrogen bond interactions) is not altered by a 180◦-rotation of the ligand around its
longest axes of inertia; these two binding conformations can also be observed in our docking
results. Because the energetic difference between the two orientations is very little, it differs
only by few kJ/mol, the different resulting conformations are not a problem of our search
Figure 7.4: Overlay of several different aligned TK crystal structures (inhibitors and water
molecules are highlighted). Ligands: two different binding orientation (carbon atoms green
or blue), Water molecules: are labeled by numbers. The water molecules are an important
criteria for the binding orientation of the inhibitor.
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strategy, but a result due to two energetic close competing conformations.
By investigating an alignment of several TK X-ray-structures, the origin for the preference
for one conformation is revealed: crystal water molecules. Their presence decides which
conformation of the ligand is more favorable.
Figure 7.4 shows the aligned X-ray enzyme structures which illustrates the two important
binding orientation of the ligands. The figure also displays different clusters of crystal water
molecules (labeled W1, W2, W3 and W4) in the overlay of different enzyme structures.
Modeling the water molecules is very difficult. These water molecules can mediate a hydrogen
bond network from the ligand to the enzyme, can be pushed aside from the ligand to become
part of the bulk solvent: enthalpic and also entropic energy contributions have to be evaluated.
Simulating explicit water molecules during a docking simulation is a challenging problem, since
the complexity of the system increases dramatically and also since the entropic change, if the
water molecule is freed or not, has to be quantified 1.
7.3.3 Flexible Protein Screen
The results of this screen are summarized in figure 7.1 (right panel), the scores of the individual
inhibitors are listed in the column labeled ‘6 flex’ in the table 7.1. Now all ten ligands achieved
a negative binding energy. As expected, the number of database compounds that achieved
a negative and higher binding energy increased as well, because a flexible conformation of
the enzyme reduced the bias of the screen against a specific binding pattern. Since 4251
compounds had now got a negative binding energy (compared with 3291 ligands of the rigid-
model run), the diversity of the docking tool had increased by roughly 30%. At the same
time, the specificity had decreased because the ‘lock’ now allowed for a broader class of ‘keys’
to fit into.
It was also observed that the accuracy of the flexible model screen was lower than that of the
screen using a rigid enzyme model (with the same number of function evaluations) because
the number of degrees of freedom has increased. In the figure 7.1 the docking energy error is
proportional to the width of the cone of the corresponding ligand.
In all investigated X-ray enzyme pockets an additional co-factor (SO4) is present. Its position
is almost invariant in the observed X-ray structures. The SO4 co-factor is strongly stabilized
by a dense hydrogen-bond network with the enzyme. On the other hand, all of our ligands
have more than 20 atoms and accommodate worse to the local hydrogen-bond network than
this co-factor. Consequently the energetic cost to push the co-factor aside should be very
high.
Because we are interested in ligands with a high affinity, we restrict our docking simulations
also only to those possible binding conformations, which may lead to a high affinity.
In a second flexible screen, summarized in figure 7.5, we additionally added the co-factor to
1At the current version of FlexScreen we allow some movable water molecules. At the end of each stage the
water molecule conformations are optimized and if favorable, these interactions are evaluated for the binding
energy; if not, these interactions are neglected.
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Figure 7.5: Histogram of the binding energies of the docked ligands after a screen to the TK
enzyme [pdb code: 1E2H] (positions of the known inhibitors are highlighted). 5 side chains
of the enzyme were treated flexible. Additionally also the co-factor SO4 was included for the
screen.
our previous flexible enzyme structure. Because its position appeared to be almost invariant
in the observed X-ray structures, it was kept fixed during the simulation. Another benefit of
the inclusion of the co-factor is, that the enzyme pocket is now completely closed. In previous
screens some enzyme-ligand conformations were partly in contact with the bulk solvent. Such
conformations are not possible here.
As a result, 4058 of 10000 ligands now docked to the target, a little less than before due
to the sterical restrictions. Comparing the figure 7.5 with the flexible screen of figure 7.1
shows that the binding energies of the ten active compounds with the additional co-factor are
not very different from the previous flexible screen. As in the crystal structure their binding
conformations are nearly independent from the SO4-group.
7.3.4 Comparison: Rigid screen vs. flexible screens
To quantitatively compare different screens against the same ligand database, it is sensible
to assign an overall score to each screen which rates its performance [89]. We computed
such a ‘score’ for the entire screen from the ranks of the docked known inhibitors among the
N = 1000 best ligands (uppermost 10%). This score is computed as the sum of N −P where
P is the rank of the known inhibitor and shown in the bottom row of table 7.1. An inhibitor
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ranking in the top of the screen contributes a score of 1000 to the sum, a badly ranked
inhibitor comparatively little. Because the best N ligands are evaluated, screens which dock
many known inhibitors with moderate rank may have comparable scores with screens which
perform perfectly for one inhibitor, but fail for all others.
With a score of 5225, the rigid enzyme screen displayed the poorest performance among all
screens, because the individual binding patterns of the inhibitors are not supported by a rigid
enzyme structure.
In comparison the flexible model screens performed much better. With a score of 6576 and
7063 for the screen with the additional co-factor, these results indicate that the increase in
diversity of the technique had out-balanced the decrease in specificity, leading to an overall
better docking performance of the screening tool.
7.4 Discussion
The necessity to account for the dynamic behavior of a protein has been recognized and
discussed [25, 24] for a long time. A single fixed protein structure is often not an adequate
model for the dynamical ensemble of structures assumed by the protein. The low energy
conformations of a protein may comprise several different side chain orientations which differ
by less than 1 kT. Additionally the protein may slightly change its low energy conformation
upon ligand binding [25].
In previous studies, Merlitz et al. [109], tested the impact of rigid protein structures on
the result of docking simulations. In these studies the binding affinity of the native and the
native-like ligands to the fixed protein structure was overestimated. In comparison with other
good binding ligands, the ligand of the native protein structure docked significantly better
than dissimilar compounds that also have a high experimental affinity.
One possibility to tackle this problem is to perform several docking simulations to different
rigid protein structures and then unite all the different results in a consensus score for each
ligand. For this purpose, strategies were developed to identify a minimal set of flexible side
chains, that allow a generation of a sufficient large structural ensemble of the protein for later
rigid docking simulations [3].
In our study we present a different approach. Before docking we identify possible side chains
which may change their conformation during the docking simulation. We compared differ-
ent protein structures with each other and could therefore identify flexible side chains. In
this study, we use the ligand-free structure of the enzyme thymidine kinase for the docking
simulations. Employing ligand-free structures of a protein with flexibility at the active site
is often disadvantageous for docking studies. On the one hand the starting structure is not
biased to any known native ligand, but on the other hand the active site of the protein can
be narrower than in the complexed structure, because the protein can also accommodate to
ligands by minor backbone movements.
Our results demonstrate the shortcomings of a rigid protein structure for virtual screening.
74 Chapter 7. Importance of Protein Flexibility
Similarly to consensus scoring, our results suggest that the inclusion of side chain flexibility
for the enzyme leads to a less biased score of high-affinity ligands, because important different
binding modes are available for a higher variety of ligands. A fixed protein structure has a
high specificity for those ligands which are similar to the ligand the protein originally formed
a complex with. Including at least partial flexibility for the enzyme allows a by far wider
class of ligands to dock well.
As a consequence, differences in the enrichment ratio for different scoring functions [13] may
depend more on the suitability of the enzyme or receptor conformation and environment than
on the quality of the scoring function.
By using an additional co-factor in the enzyme structure, we investigated, how restrictions
change the docking results. The SO4-group occupies a favorable position in the enzyme struc-
ture and several polar residues are blocked for direct ligand-interactions. Since the co-factor
is strongly stabilized at its position, it is energetically unfavorable to remove it.
In the docking studies without the co-factor, the affinity of the ligands which have direct
interactions with those residues which are blocked if the co-factor is present should be re-
evaluated. The affinity of these ligands must be lower, because of the energetic cost to push
the co-factor aside. Several approaches are possible for this problem. Since we are solely in-
terested in high affinity ligands (the top 10% of the database), we decided against an energetic
penalty for replacing the co-factor. As a consequence of the restricted cavity and also of the
restricted amount of different conformations, the accuracy of our docking screen increases. In
the screen with the additional SO4, we notice the highest score. From this we learn, that it is
an advantage to use as much information as is available on a system and incorporate it into
the docking simulations. When analysing protein structures it should be also investigated if
co-factors are present and which of them are likely or unlikely to be removed. Exploiting this
information may result in docking screens with a higher accuracy.
Our results demonstrate the importance of crystal water molecules for binding orientation
and affinity. As in a previous study (see section 6.4.2), not all water molecules are displaced
upon ligand binding. Some water molecules are stabilized in the hydrogen bond network and
their dynamic displacement would need a detailed analysis of enthalpic and entropic energy
contributions. These contributions would have to be considered for the affinity of a ligand.
Such an analysis is still very difficult presently. In our study, we observe the influence of these
strongly bound water molecules on two competing ligand binding orientations. Comparing
several enzyme crystal structures, we observe five different probable positions of crystal water
molecules. These water molecules seem to determine which of the competing binding orien-
tations is favored.
Very recently, we implemented the treatment of displaceable water molecules (translation, ro-
tation and a total removing) during docking. This method enables us to repeat the study by
including the displaceable water molecules. In a prospective study it will be very interesting
to investigate the influence of the new method on the docking results.
Chapter 8
Influence of QM Descriptors on
Docking Simulations
In this chapter, we investigate, if it is possible to incorporate quantum mechanical calculations
into our characterization of proteins and ligands and if it is advantageous for the docking
accuracy.
In our program FlexScreen proteins and ligands are described with the following properties:
Atom types, partial charges, positions, bonding topology and bond types. Especially, the
partial charges resulting from the molecular charge distribution can often not be determined
accurately. It depends on the connected atoms, bond types and also the neighboring atoms.
In this study, we investigate a method to improve the partial charges by ab initio quantum
mechanical calculations. We present a methodology with which the accuracy of the docking
results increases and still can be used for high-throughput screening.
8.1 Introduction
As our study with the Astex/CCDC study shows, recent docking methods permit the pre-
diction of the binding mode to high-accuracy with modest computational cost. The accuracy
of the scoring function for the affinity estimate thus emerges as the most important deter-
minant for the success of this approach [13, 154, 87]. It is presently controversial whether
simple scoring functions based on biochemical/biophysical models, henceforth called inter-
action based scoring functions (IBSF), are capable to adequately represent the complex
interactions that stabilize ligand-protein complexes or whether knowledge based potentials
[166, 33, 64, 14, 112, 115, 67, 55, 165, 79] offer more promising results. While many meth-
ods perform well in the prediction of binding modes, the correct estimation of the affinity
remains a significant outstanding challenge. Recent developments of linear-scaling quantum
chemistry methods now permit the quantum calculations on large molecules, such as protein
fragments [52, 49, 84, 83, 119, 120, 129]. Large scale applications of semi empirical quantum
chemical methods for protein characterization [133, 129, 132, 122, 163] have recently shown
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good correlation between observed and calculated affinities for a large class of compounds.
In this study we investigate two receptors, in which ligand binding is mediated not only by
direct ligand-receptor interaction, but also by indirect stabilization of water molecules.
We compare purely classical force field-based scoring functions with quantum-derived scoring
functions in the description of these systems: Estrogen is a steroid hormone that plays an
import role in the regulation of tissue growth, differentiation and homeostasis. Estrogens
also play an important role in bone maintenance, in the central nervous system and in the
cardiovascular system where estrogens have certain cardioprotective effects [91, 162, 39, 69] .
Estrogens diffuse in and out of cells but are retained with high affinity and specificity in target
cells by an intranuclear binding protein, termed the estrogen receptor (ER). Once bound by
estrogens, the ER undergoes a conformational change allowing the receptor to interact with
chromatin and to modulate transcription of target genes [72, 11, 161].
All nuclear receptors function as ligand-activated transcriptional factors and possess a com-
mon domain structure, comprising a conserved DNA-binding domain, variable hinge-regions
and conserved ligand-binding domains. The understanding of ER receptor function and the
identification of further potential ligands to the ER thus remains an important goal. A num-
ber of compounds other than estrogen have been identified as potential ligands of the estrogen
receptor, some of which might induce hormone-like effects on humans and animals.
The retinoic acid receptor (RAR) is also a member of the nuclear receptor superfamily [58].
Its ligand-binding domain (LBD, molecular mass 30 kDa) contains the ligand-dependent ac-
tivation function [113]. RAR (in complex with the retinoid X receptor (RXR)) binds to their
target DNA sequences and activate transcription in the presence of retinoic acids, the biolog-
ically active metabolites of vitamin A. Retinoids are involved in the regulation of cell growth,
differentiation and apoptosis, processes that play an important role in embryonal development
and postnatal life [26] and that are the basis for the use of retinoids in cancer prevention and
treatment [100, 68, 94]. The RAR family is composed of three genes leading to the α, β and
γ isotypes that correspond to distinct pharmacological targets [26], the γ subtype is studied
here.
For the estrogen receptor [13, 153, 27, 29, 184, 35], the determination of binding modes and
affinities is further complicated by the indirect stabilization of most ligands through a hy-
drogen bond network involving a conserved water molecule, binding key residues (GLU353,
ARG394, LEU387 side chain and backbone) on the one side of the binding pocket in competi-
tion with electrostatic interactions with a histidine residue (HIS524), at the opposite corner of
the biding pocket (see figure 8.3). A balanced description of these competing interactions thus
emerges as an important prerequisite for affinity predictions. High dimensional QSAR stud-
ies demonstrate a high correlation between experimental affinities and theoretical estimates
based on a multitude of possible binding modes [164], but require significant pre-existing data
for parameterization. Standard docking methods [13] identify known binding modes well, but
fail to correlate the estimated affinity with the experiment.
For both proteins a large environment of the ligand binding site was recently characterized
using the fragment molecular-orbital method (FMO)[51]. FMO permits quantum-chemical
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Figure 8.1: Illustration of the ligand binding site of ERα. The top panel illustrates the
overall binding site in the ERα (ligand EST shown in black), the lower panel the vicinity of
the binding pocket with the residues that were treated in the quantum-chemical calculation
in blue and red. The residues that were flexible in the docking simulations are shown in red.
The surface around the ligand (EST) illustrates the interaction hot spots with the receptor,
the conserved water molecule is visible in a ball-and-stick representation of the left side of the
ligand.
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Figure 8.2: Illustration of the binding pocket of RAR in complex with AT-RA.
Figure 8.3: Illustration of the ligand-receptor interaction binding site of ERα. The ligand 17β-
Estradiol is stabilized by a hydrogen bond network with a conserved water and the residues:
GLU353, ARG394 and LEU387 .
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calculations of large bio-molecules using a variety of established quantum-chemical techniques
beyond the semi-empirical level. Here we derive classical electrostatic models from the partial
charges of the quantum calculation and used them in our docking simulations [84, 83, 119, 120].
We docked a set of quantum mechanically characterized ligands into the ERα and RAR re-
ceptor structure using both force field based functions (FSF) and the quantum based scoring
function (QSF). For ERα we find a significant increase in the correlation between computed
and measured affinities for these compounds, when the QSF model is used. We demonstrate,
by directly comparing QSF and FSF results, that this improvement is rooted in the quality
of the quantum-based electrostatic model. For the RAR receptor we find a very good corre-
lation between experimental and computed binding affinities using both purely classical and
quantum based receptor descriptors. Our results therefore demonstrate a viable route for the
development of receptor specific interaction based scoring functions that may improve the
accuracy of affinity predictions for in-silico drug discovery.
8.2 Ligands, Receptor Structure and Partial Charges
The ERα (pdb code 1ERE) was previously characterized at the HF/STO-3G level using the
fragment molecular orbital (FMO) method, both in a ligand free conformation and in com-
plex with the ligands:17β-Estradiol (EST), Diethylstilbestrol (DES), Raloxifene (RAL), 4-
hydroxytamoxifen (OHT), Genistein (GEN), Tamoxifen (TAM), 4-hydroxyclomifene (OHC),
Clomifene (CLO), 17-Estradiol (ESTA), Bisphenol A (BISA) and Bisphenol F (BISF)[51].
Because quantum calculations are computationally very expensive, even with the FMO-
technique [84], the binding energies for the ligands were calculated with respect to the most
important fifty-amino acid subset of complete protein receptor structure (50 amino acids).
This subset (model 2 in [51], see figure 8.1) includes the most important residues for ER-
ligand. The hydrogens in the receptor structure are optimized by CHARMm force field
calculations [22], in addition the hydrogen bond network of an even smaller model, consisting
of a ligand, a water molecule and the residues GLU353, ARG394, LEU387, HIS524 of the
receptor structure (1ERE) were optimized at the HF/6-31G(d) level. Binding energies were
calculated as the difference of the FMO energy of the receptor free-structure and the ligand
in isolation to the FMO energy of the complex[51].
For the docking study with RARγ we performed docking simulations to the rigid receptor
structure of RARγ in complex with the all-trans retinoic acid ligand (AT-RA) (pdb code:
2LBD [136]). With three other ligands we performed docking simulations to this receptor
structure: 9-cis retinoic acid (9C-RA), CD564 and BMS181156. The modeling of the ligands
and the receptor followed the same procedure as for the estrogen receptor.
For the quantum-based models of the present investigation, we extracted Mulliken partial
charges for the receptor and ligand atoms. These Mulliken charges are calculated from the
charge distribution of the FMO calculation. For the classical based models partial charges
were assigned using the ESFF-force field [149] in InsightII [70] (at pH 7.4), which provides
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an adequate assignment of the charges for both the protein and a wide variety of ligands.
ESFF succeeded to automatically assign consistent charges for over 180,000 ligands of the
NCI Open database (210,000 ligands), and we used the same assignment procedure here for
consistency.
In contrast to the FMO study [51] we use a single flexible receptor model for all docking
simulations. The rigid part of the receptor was taken from the ERα in complex with EST.
Based on a comparison of all receptor models in the FMO investigation the six side chains
(MET343, HIS524, LEU525, ILE424, THR347, LEU354) were made flexible (see figure 8.1).
Since the computational cost rises with the number of flexible sidechains we have not imple-
mented an automated selection scheme for the flexible side chains.
The docking simulations use a cascaded approach (see section 5.1): the total number of sim-
ulation steps is divided into several partitions of similar computational effort. In the first
partition 100 simulations with 7500 computational steps, in the second partition 5 simu-
lations with 30000 computational steps and in the third partition 2 simulations with 75000
computational steps are performed. In partition 2 and 3 only the best energetic trajectories of
the former partition are continued to simulate. To avoid in partition 2 a simulation of nearly
identical conformations, we divide the final 100 conformations in stage 1 into three different
clusters: cluster 1 includes the best-scoring conformation and all others with a similar binding
pose (RMSD less than 0.8 A˚), cluster 2 includes the best-scoring ligand outside cluster 1 and
all conformations with a RMSD of 0.8 A˚ and cluster three contains all other conformations.
We start stage 2 with the two top-scorers of clusters 1 and 2 and the top-scorer of cluster 3.
For partition 1 we use 3 different starting conformations which are randomly selected for each
of the 100 simulations: a relaxed conformation, a conformation with largest atom-to-atom
distance and a conformation with smallest radius of gyration (see section 5.4).
8.3 Results
For ERα docking simulations were performed with 11 different ligands and the binding ener-
gies were compared to available experimental affinities. We employed different electrostatic
models for ligands and receptor, respectively. In the force field-based scoring function (FSF)
partial charges were assigned using a classical force field and in the quantum-based scoring
function (QSF) partial charges were derived from the FMO model described (see section
8.2). For each ligand we perform 10 independent simulations using the same docking pro-
tocol (section 8.2) and calculate the median docking energy and the standard deviation.
Table B.3 (see appendix) summarizes the estimated binding energies for all these calcula-
tions. Commensurate with previous studies FlexScreen (see chapter 6) reproduces the bind-
ing modes of the quantum chemical calculations to within less than 1 A˚ root-mean-square
deviation (RMSD) in either model. Figure 8.4 shows typical examples for the calculated
receptor-ligand configurations in the QSF model: the left panel of figure 8.4 shows the bind-
ing mode of Diethylstilbestrol (DES) in complex with ERα. With a RMSD of just 0.63A˚, we
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Figure 8.4: Superposition of binding modes from the FMO calculation and and FlexScreen
for diethylstilbestrol (DIS) and 17α-Estradiol (ESTA), respectively. The grey colored ligand
represents the ligand, which position was determined by quantum mechanical calculations
and the ‘colored’ ligand illustrates the binding mode calculated by FlexScreen.
successfully find the ‘native’ binding mode in eight of the ten simulations. The right panel il-
lustrates the calculated binding mode for 17α-Estradiol (ESTA) in complex with ERα, where
the FlexScreen pose deviates from the crystal structure binding mode (augmented by some
hydrogen optimization[51]) by 0.83 A˚ — the binding mode on the basis of the classical calcu-
lation clearly captures the main binding motif of the quantum calculation for the same ligand.
Table 8.1 summarizes the deviation between the experimental and the predicted binding mode
in the docking simulations for all ligands where crystal structures of the complex are avail-
able. We note that there is little difference between the binding modes between the different
ERα
EST DES RAL OHT
1ERE 3ERD 1ERR 3ERT
QSF 0.73 0.63 1.94 0.85
FSF 1.70 0.66 2.23 0.97
RAR
ATRA 9CRA CD564 bms181156
2LDB 3LDB 1FCY 1FCZ
QSF 0.436 0.918 0.844 1.154
FSF 0.418 0.919 0.845 1.161
Table 8.1: Median RMS deviation (in A˚) between the experimental and the calculated binding
mode for the ligands where crystal structures are available. The ligand names are followed
by the pdb-id of the crystal structure that was used for comparison and the RMSD values for
the QSF and FSF models respectively.
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scoring functions. Differences in estimated binding energies/affinities thus originate mostly
from differences in the representation of the interactions.
These results are a first evidence that the QSF model describes the inter- and intramolecular
interactions sufficiently well to reproduce the key features of the binding mode. Using the
QSF model we find the correct binding mode in 68% of all simulations: Of 110 independent
runs 75 have a RMSD < 2.0 A˚ to the binding mode determined in the quantum calculation,
which demonstrates the reliability of the FlexScreen docking protocol. For the FSF model
the fraction of reproduced binding modes drops to 55% (of 110 simulations only 61 had a
RMSD of less than 2.0 A˚), indicating that the two models stabilize slightly different binding
conformations. These fluctuations in the binding mode are mirrored in fluctuations of the
binding energies obtained in the 10 independent simulations for each ligand. We notice that
on average the standard deviation of the energy of the FSF model is almost twice as large as
that of the QSF model.
Figure 8.5 (upper panel) illustrates the correlation between the FMO binding energies and
the QSF/FSF models. The regression coefficient increases from R=0.71 for the FSF model to
R= 0.94 for the QSF model. The binding energies computed in the purely classical model on
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Figure 8.5: Correlation between binding energies in the QSF (diamonds) and FSF (squares)
models with the binding energies in the FMO quantum chemical calculation for 11 ligands
to the estrogen receptor. The lines indicate least square fits to the data, the correlation
coefficients are indicated. The bottom panels give the residual errors of the QSF and FSF
model (from top to bottom) to the line of regression.
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the basis of the receptor-specific partial charges almost perfectly capture the full quantum-
mechanical interactions with the protein environment. It is important to note that no extrane-
ous binding modes arise as a result of the approximate charge model. These data demonstrate
that the electrostatic interactions are very well represented in the scoring function derived
from the quantum calculation. It should be noted that the ESFF force field, which we used
for comparison, gives excellent results for the thymidine kinase [107] (see chapter 7) and dihy-
drofolate reductase receptors [106]. Of additional interest is also the correlation for a mixed
model in which the protein is described with quantum partial charges, while the ligands are
treated with a classical force field. Such a mixed model might be used for screening a large
ligand database, in which a quantum-chemical calculation for all ligands may be infeasible.
A regression coefficient of R = 0.79 indicates that only part of the accuracy gain in the QSF
model is retained.
We have also directly compared the computed binding energies in both models with rela-
tive binding affinities measured in experiment, which are available relative to EST for 8 of
the 11 ligands. Only relative binding affinities are available [92], which were measured by
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Figure 8.6: Correlation between binding energies in the QSF (diamonds) and FSF (squares)
models with experimental relative binding affinities (relative to the ligand EST ) for 8 ligands
to the estrogen receptor (without solvation energies). The lines indicate least square fits to
the data, the correlation coefficients are indicated. The bottom panels give the residual errors
of the QSF and FSF model (from top to bottom) to the line of regression.
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a solid-phase binding system as a screening assay [60] in which the selected ligand displaces
a radio-labeled ligand. The signal detection is based on the fact that 3H emits low energy
electrons that have a very short range in solution and therefore only the radioligands bound
to receptors triggers a scintillation process. Therefore, the docking results are transformed in
relation to the affinity of ligand EST:
∆∆ELigand = ∆ELigand −∆EEST . (8.1)
Figure 8.6 again illustrates that the quantum-derived scoring function (R=0.68) performs
much better than the purely classical scoring function (R=0.37). Including QM parameter
into the force field improves also the accuracy of the binding energy in relation to experimen-
tal affinities.
Since the models lack de-solvation terms, such comparison cannot be expected to yield quan-
titative agreement. In order to improve the comparison we have post-scored the QSF/FSF
models with a GB/SA type solvation model (see section 5.3) that can approximately account
for the differential de-solvation effects of the ligands. Because the receptor pocket of ERα
is almost completely filled with the ligands, considered in this study, differential de-solvation
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Figure 8.7: Correlation between estimated affinities of the QSF with solvation corrections (di-
amonds) and the FSF (squares) models with experimental relative binding affinities (relative
to the ligand EST) for 8 ligands to the estrogen receptor. The lines indicate least square fits
to the data, the correlation coefficients are indicated. The bottom panels give the residual
errors of the QSF and FSF model (from top to bottom) to the line of regression.
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effects of the receptor are not expected to play an important role. We transform our results
for the different ligands correspondingly with the ligand de-solvation energies (listed in table
8.2).
LIG EST DES RAL OHT GEN TAM ESTA BISA
QSF -9.64 -12.03 -14.94 -15.72 -7.44 -19.25 -11.05 -9.32
FSF -5.27 -5.10 -5.87 -12.51 2.16 -16.91 -6.23 -2.70
Table 8.2: De-solvation energies of the 8 ligands calculated by the GB/SA model for the two
different force fields QSF and FSF
Figure (8.7) shows the correlation of the computed results to the experimental affinity values
of log(RBA/100). For the QSF model we find a very good correlation to the experimental
data (R = 0.81), which is by far higher than that of the FSF model (R = 0.54). As above
we have additionally investigated a mixed model, where partial charges for the receptor were
derived from the quantum calculation, while the ligands were parameterized with ESFF. For
this model we also find a high correlation (R = 0.78) [R = 0.52 without the de-solvation
energy], data not shown, which is again significantly higher than with ESFF alone.
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Figure 8.8: Comparison of two docking simulations to the RAR receptor. The receptor is
described one time with the FSF and the other time with the QSF force field. The results of
the binding energies for four ligands (AT-RA, BMS81156, 9cRA and CD564) are plotted in
comparison to experimental results (logKD).
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The results for the RAR receptor are similarly encouraging. As figure 8.8 illustrates we
obtain a correlation of R=0.93 and R=0.92 when correlating the experimental affinity with
the binding energy obtained with the QSF and FSF, respectively. The correlation of the
binding energy with that obtained by the quantum calculation is even higher (R = 0.99 and
R = 0.98, respectively). For consistency we have computed the same de-solvation corrections
used for the estrogen receptor, which do not affect the the observed correlations. Including
these terms we obtain a correlation of R=0.95 for the QSF and R=0.93 for FSF model. The
deviation between the computed and the experimental binding modes varies from 0.4-1.6 A˚,
as detailed in table 8.1.
8.4 Discussion
The development of accurate, yet fast in-silico screening protocols remains a daunting task.
While there is a growing consensus that serval docking methods are well suited to predict
binding modes of small molecules to well characterized proteins to near-experimental ac-
curacy [175], the development of quantitative methods to estimate the affinity remains a
significant challenge. The estrogen receptor, where receptor-ligand binding is mediated by a
conserved water molecule for many ligands is a good example for such a system. A compara-
tive study for investigating several docking protocols and scoring functions found that binding
modes are well predicted, while affinity estimates remain poor [13]. In the presence of many
well characterized ligands, high-dimensional QSAR methods can be used to parameterize the
interactions to achieve a high correlation between computed and estimated affinity [153, 164].
Similarly high correlation may be obtained using alternate heuristic schemes [29, 184, 35] or
as heuristic post-scoring as the comparative molecular field analysis method [180].
These methods, however, fail to address the fundamental question how to improve scoring
functions for in-silico screening tools in the absence of protein-specific experimental data.
Many present day docking strategies use knowledge based scoring functions that average over
many known protein-ligand complexes in the hope to generate a good ranking also for differ-
ent ligands. Alternatively one may try to improve force field based scoring functions using
quantum chemical models to parameterize a specific protein [133, 129]. Given the complexity
of quantum chemical calculations for whole proteins or significant parts of the protein en-
vironment and the difficulty to parameterize models that combine classical force field terms
with protein specific parameters obtained from other sources, these methods are still in their
infancy.
Here, we investigated the binding energies for eleven typical ligands to the binding domain
of the human estrogen receptor ER-α. We find that binding energies calculated at the quan-
tum chemical level correlate very well with those obtained with a classical scoring function,
provided that the classical scoring function is parameterized with charges obtained from the
quantum calculation. This result does not hold, when an all-atom force field is used to obtain
charges for the ligands and receptor, indicating that the use of quantum charges may improve
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the accuracy of binding energy calculations in high throughput screening applications. This
conclusion also carries over, when calculated affinity estimates are correlated with relative
binding affinities measured experimentally.
These data demonstrate that electrostatic potentials obtained from quantum calculations be-
yond the semi-empirical level can be used in conjunction with classical force field based scoring
functions to improve the affinity estimates for the particularly complex ERα receptor. We
find that the binding modes are equally well predicted with FSF and QSF based simulations,
so that the improvement in the affinity estimate stems from the improved treatment of the
electrostatic interactions in the QM model.
Even higher correlations for the measured and predicted affinities were also observed for the
QM derived scoring function of the RAR receptor, where quantum methods were also advo-
cated in the search for new antagonists [152]. Recent studies of the related retinoic X receptor
also required the specific adaptation of the scoring function [156] to obtain adequate results,
which an earlier screen of the Available Chemicals Directory (MDL Information Systems,
San Leandro, CA), a compound structure database of over 150,000 molecules, using the ICM
scoring function resulted in a single novel antagonist [141].
8.5 Conclusion
The development of accurate scoring functions for complex protein-ligand binding interactions
remains a difficult task. The increasing availability of quantum calculations for large protein
fragments or even entire proteins offers exciting possibilities for the design of protein specific
scoring functions to improve force field based scoring functions for in-silico screening [133].
Our data demonstrates that it may be possible to transfer electrostatic potentials from quan-
tum calculations to develop such protein specific interaction based scoring functions. This
approach has the advantage that it does not require pre-existing experimental data for the
given protein, while still producing adequate models to describe the interactions.
As quantum chemical calculations for large biomolecular systems, such as those of the FMO
method exploited here, become more accurate, protein specific interaction based scoring func-
tions may help to capture the specifics of a particular system. Our study demonstrates that
such an approach can work for post-semiempirical quantum methods; much work remains
to be done before a generic protocol for the derivation of such protein specific functions is
established. It complements other work [132, 122], where methods of quantum mechanics are
used to improve structure based drug design.
It should be noted that the high cost of quantum chemical calculations at the ab-initio level
(HF or higher) is no major deterrent for the derivation of such models. The protein character-
ization at the quantum level is required only once, while the resulting model can subsequently
used for ten-thousands of binding simulations, which dwarf the cost of the quantum calcula-
tion to define the scoring function.

Chapter 9
Summary
In the projects reported in this thesis, we have investigated novel simulation protocols for
the rational development of drugs. To this end, we have developed a new high-throughput
protein-ligand docking method. This method employs the three-dimensional structural infor-
mation of the protein to identify new compounds that bind with a high affinity to the protein.
In chapter 6, we show that our simulation approach reproducibly determines known binding
modes with high accuracy [42]. This evaluation is an important test to prove the validity of
the scoring function and the search method. The scoring function approximates the receptor-
ligand interactions employing several different energy potential types. A good scoring function
should be able to identify a native protein-ligand conformation, i.e. a conformation that is
observed experimentally, as the energetic global minimum on the potential energy surface of
the protein and the ligand. This can only succeed if the docking tool used is able to locate
the global minimum on the potential energy surface with great reliability and speed. For this
purpose, we employ the stochastic tunneling search method.
In the evaluation of our approach, we successfully show that both the scoring function and the
search method can reproduce known binding modes. These results demonstrate the validity
of our docking method and allow us to apply our approach in further studies, in which the
ligand affinity and the native protein-ligand conformation are not known.
It is therefore important to develop a methodology that further improves the accuracy of
the calculated binding energies and the binding modes for ligand database screens. As one
way out of this dilemma, we attempted to improve our force field based scoring functions
by augmenting it with receptor-specific data obtained from quantum-chemical calculations.
With our study of the estrogen receptor and of the retinoic acid receptor [43], presented in
chapter 8, we compare scoring functions derived from purely classical models with those de-
rived from quantum-chemical calculations with respect to experimental affinities. Because the
electrostatic interactions in proteins and protein-ligand complexes are very complicated, the
assignment of protonation states and partial charges is one major determinant of the stability
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of particular complexes. The choice of these parameters is one of the most important ingredi-
ents of a molecular-mechanics type scoring function. We have therefore attempted to augment
scoring functions derived from standard force fields, which describe many properties of pro-
teins and ligands sufficiently well, by receptor-specific partial charges and protonation states
from quantum mechanical calculations (QM). Employing results of the fragment molecular
orbital (FMO) method, receptor specific scoring functions (here based on quantum derived
partial charges) were integrated into our protein model. We then compared the docking re-
sults using scoring functions derived from purely classical models with their hybrid cousins:
We find that the highest accuracy can be obtained by incorporating the QM derived partial
charges into the ligand and also into the receptor model. By integrating QM derived partial
charges into the receptor model only, we still see a significant increase of accuracy compared to
our standard receptor model. These results are very important for high-throughput screening
docking tools: Even though QM calculations for the receptor structure are very time consum-
ing, this effort has to be invested only once, before the actual screening of the ligand begins.
Due to the separability of scoring function parameterization and the actual docking calcula-
tion, the accuracy of the screen improves with little increase in the overall computational cost.
In chapter 7, we show the advantage of our flexible protein model in the docking study
of the thymidine kinase enzyme (TK). Using only one rigid protein structure for docking sim-
ulations generates an artificial constraint on particular ligands. Ligands which have a binding
mode similar to the native ligand of the used protein structure benefit from this constraint
and appear to dock better in the simulation than dissimilar ligands with equally good exper-
imental affinities.
However, a protein is a dynamic structure: Due to the thermal activation energy, a protein
is constantly subject to slight conformational changes in the backbone or, even more impor-
tant, in the protein side chains. If a ligand and a protein form a complex, the ligand is able
to induce small conformational changes to the protein structure without high energetic cost
(usually in the order of kT). As a consequence, compared to the ligand-free structure, we
observe a slightly different three-dimensional structure for the protein when bound to the
ligand. Often, these conformational changes can be traced back to conformational changes of
the side chains only.
In the TK study (see chapter 7), we investigate if advantages can be observed using a protein
model with flexible side chains in large-scale docking simulations. We analyze the confor-
mational changes of a flexible side chain upon docking with different ligands and compare
these ligand and side chain orientations with the known binding conformations obtained from
crystal structures. We observe very similar structural conformations in our model compared
to the crystal structures. These results prove that in the case of the TK enzyme our protein
model with several flexible side chains can well approximate the dynamic protein that accom-
modates to different ligands by different conformations.
In large database screen, we compare the docking results of 10000 ligands with 10 ligands of
known high affinity to TK. The database screens are performed using a rigid enzyme struc-
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ture and flexible protein models. Here, we demonstrate the superiority of our flexible protein
models also quantitatively. Due to being less biased to only a few ligands, our flexible protein
models identify the active compounds with higher accuracy by comparing the energetic rank
of the active compounds with the ligands of the database.
Additionally, in this study, we observe the importance of crystal water molecules for protein-
ligand docking. Crystal water molecules are water molecules which are strongly stabilized in
the protein. These molecules often can not be neglected in docking studies. Their presence
or absence may determine the final protein-ligand conformation. Observations like these also
guide our present research endeavors. Recently, we have developed an extension to our ap-
proach that explicitly incorporates crystal water molecules as movable and removable parts
of the system (not included in the thesis).
Through our studies, we have successfully developed a high-throughput docking approach
which allows us to identify well binding ligands in large databases. The inclusion of protein
flexibility by allowing side chain flexibility proved to be an advantage over using only one
rigid protein structure for our docking simulations.
Outlook
Our approach has proved to be useful, but we also observe difficulties which have not yet
been addressed. Sometimes, the ligand-induced conformational changes of the protein can
not be approximated solely by side chain flexibility. For example, docking Staurusporine into
the ligand-free protein kinase structure does not work with our present methodology because
backbone movements must also be taken into account. We are presently starting to work on
challenging cases like these and integrate local backbone movements into our approach.
Another field for improvements is the scoring function. For the studies presented in this the-
sis, the solvent contribution was only, if at all, taken into account for the ligands. For more
opened cavities this approach does not prove to be successful.
In the current version, the solvation energies of the ligand-protein complex are calculated
during the docking simulation. For each atom, the solvent accessible surface area (SASA) is
determined and the solvation energy of the complex is calculated as the sum over all atoms
of the SASA per atom multiplied by an atom type specific factor. These SASA atom-type
specific parameters can not be derived analytically. At the moment, we are searching for the
optimal parameters in reference to our current force field.
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Other parts of the scoring function also need to be improved making further research neces-
sary:
1. Pi-stacking: Aromatic rings are stacked together by an overlap of p-orbitals. This in-
teraction type can not be calculated by usual attractions of a van der Waals interaction.
The interaction differs in strength and geometry. Therefore, a new potential type has
to be implemented that takes the pi-stacking interaction into account.
2. Transition metal interaction: It is often the case that the ligand coordinates with tran-
sition metals. These interactions depend on the geometric coordination group of the
transition metal. Such effects are not considered in our scoring function. Integrating
and parameterizing these interactions into a scoring function is very challenging and
will be a study in its own.
Our approach is well suited for protein-ligand systems for which solely the structural informa-
tion of the protein is available. If no native inhibitor is known, it is not possible to search for
well-binding compounds by similarity. Very recently, for example, a new strategy for fighting
the HIV-virus was discovered. Zhou et al. [185] structurally resolved one of the viruses’ flex-
ible proteins that does not alter during the mutation. This protein is important for the virus
to attach to cells in the organism. With discovering the protein’s structure the first step has
been done and the search for inhibitors can start. These inhibitors can hopefully be used to
prevent the virus from multiplying. With our studies we aim to contribute to research efforts
like these.
Appendix A
Analytical Calculation of
Electrostatic Energies
For cases in which ligands are buried in the protein, the whole protein-ligand complex can
be approximated as a sphere, surrounded by water. Under this assumption eq. 4.16 can be
calculated analytically [82, 178, 59] and expressed in Legendre polynomials. With a minor
approximation eq. 4.16 can be written in the following form [178]
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ri, rj being the distance from the origin (center of the sphere), R the radius of the assumed
sphere with ri, rj < R and enclosed angle θ between ri and rj.
In order to apply this approximation, we first try to find the best suitable sphere for each
specific receptor-ligand complex. We start with an independent calculation of the solvation
energies for a charge of one electron at different positions in the protein cavity, using the
program APBS [8]. The different positions are usually the atom positions of a ligand and of
surrounding side chains. Then, by changing the origin and the radius of the virtual sphere, we
determine the sphere that best approximates the calculated solvation energies (least square
error).
It takes several hours to numerically calculate the solvation energies, but it has to be done
only once for the specific protein. After a suitable sphere is identified by an optimization
procedure, the electrostatic interaction and self-energies can be calculated very quickly using
the analytical eq. A.1.
The method works well for closed pockets, but it is difficult to generalize for open pockets
and cases in which the ligand docks far outside the cavity.
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In figure A.1, we compare the solvation energies at the cavity of the receptor-ligand com-
plex (pdb: 1KI2) with the analytical solvation energies of the sphere model. Compared are
not directly the solvation energies, but the solvation energies over distance. The black dots
represent the ideal analytical sphere solution. As one can see, the main behavior, predicted
by the analytical calculations, is well represented. On the other hand, outliers can also be
observed.
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Figure A.1: Comparison of the analytical solvation energies (as in eq. A.1) of 157 point
charges (black dots) in the cavity with the solvation energies calculated numerically with the
program APBS [8] (blue triangles). The 157 point charges always have the charge 1e and are
positioned at the atoms of a docked ligand and of representative surrounding side chains. As
one can see, the main behavior, predicted by the analytical calculations, is well represented.
On the other hand, outliers also can be observed.
Appendix B
Tables
Table B.1: Results of the docking test set of chapter 6: median RMSD (root mean squared
deviation of non hydrogen atoms), the number of runs yielding a RMSD < 2.0 A˚ (out of
10), root mean energy fluctuation, RMSD results of Glide, Gold and FlexX (in A˚).
Name RMSD(A˚) # < 2.0A˚ E. fluc Glide Gold FlexX
1a28 0.33 10 0.1 - - -
1a4q 0.74 10 0.1 - - -
1a6w 0.88 10 0.5 - - -
1abe 0.38 10 0.2 0.17 0.86 1.16
1abf 0.58 10 1.0 0.20 - 1.27
1aoe 0.51 10 0.1 - - -
1apt 1.04 9 7.2 0.58 1.62 1.89
1apu 0.73 10 3.1 - - -
1aqw 7.76 0 4.3 - - -
1atl 3.93 2 7.3 0.94 - 2.06
1b58 0.96 10 0.7 - - -
1bma 1.03 9 1.28 9.31 - 13.41
1byb 0.79 10 12.2 10.49 - 1.62
1c1e 5.14 0 1.0 - - -
1c5c 0.43 10 1.5 - - -
1c5x 1.88 10 0.1 - - -
1c83 0.48 10 0.1 - - -
1cbs 0.38 10 0.0 1.96 - 1.68
1cil 1.63 9 2.2 3.82 - 3.85
1coy 0.49 10 0.5 0.28 0.86 1.06
1d0l 1.11 10 9.2 - - -
1d3h 0.47 10 0.2 - - -
1ejn 0.40 10 0.3 - - -
95
96 Chapter B. Tables
Name RMSD(A˚) # < 2.0A˚ E. fluc Glide Gold FlexX
1eta 8.43 0 2.6 2.92 11.21 8.46
1f3d 0.68 10 0.3 - - -
1fen 0.56 10 0.1 0.66 - 1.39
1flr 0.58 10 0.6 - - -
1glp 0.33 10 2.3 0.34 - 0.47
1glq 1.28 10 4.1 0.29 1.35 6.43
1hfc 2.49 0 2.9 2.24 - 2.51
1hpv 1.04 10 1.7 - - -
1hsb 0.41 8 4.6 - - -
1hsl 0.79 10 1.1 1.31 0.97 0.59
1hvr 0.64 10 0.3 1.50 - 3.35
1hyt 1.08 9 1.3 0.28 1.10 1.62
1ida 1.14 10 1.4 11.88 12.12 11.95
1jap 1.40 10 1.3 - - -
1kel 6.40 0 2.2 - - -
1lcp 0.56 10 0.2 1.98 - 1.65
1lic 1.08 10 2.3 4.87 10.78 5.07
1lna 2.49 0 9.6 0.95 - 5.40
1lst 0.60 10 3.6 0.14 0.87 0.71
1mld 0.63 10 0.2 0.32 - 1.45
1mmq 0.66 10 0.4 0.92 - 0.52
1mrg 0.50 10 0.0 0.30 - 0.81
1mrk 0.86 10 0.4 1.20 1.01 3.55
1mts 0.57 10 0.2 - - -
1nco 0.34 10 0.9 6.99 - 5.85
1phd 0.95 10 0.0 1.22 0.85 0.65
1phg 0.28 10 0.0 4.32 1.35 4.74
1ppc 1.38 9 2.1 7.92 - 3.05
1pph 2.00 5 1.9 4.31 - 4.91
1qbr 0.46 10 0.6 - - -
1qbu 0.50 10 0.8 - - -
1rds 0.59 10 1.2 3.75 4.78 4.89
1rnt 1.02 10 4.7 0.72 - 1.90
1rob 1.16 10 7.3 1.85 3.75 7.70
1slt 0.87 9 2.1 0.51 0.78 1.63
1snc 6.19 0 5.4 1.91 - 7.48
1srj 7.23 0 0.9 0.58 0.42 2.36
1tmn 0.83 10 4.4 2.80 1.68 0.86
1tng 0.36 10 0.1 0.19 - 1.93
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Name RMSD(A˚) # < 2.0A˚ E. fluc Glide Gold FlexX
1tnh 0.82 10 0.5 0.33 - 0.56
1tni 2.80 0 0.7 2.18 - 2.71
1tnl 2.73 0 0.1 0.23 - 0.71
1tyl 7.37 0 0.9 1.06 - 2.34
1ukz 6.21 0 0.7 0.37 - 0.94
1wap 0.26 10 0.3 0.12 - 0.57
1xid 3.22 1 5.0 4.30 0.92 2.01
2ak3 0.45 10 0.3 0.71 5.08 0.91
2cmd 0.55 10 0.4 0.65 - 3.75
2cpp 0.37 10 0.7 0.17 - 2.94
2ctc 1.64 10 0.8 1.61 0.32 1.97
2fox 0.84 8 10.4 - - -
2gbp 0.66 10 1.6 0.15 - 0.92
2qwk 0.97 10 2.2 - - -
2tmn 1.22 10 1.1 0.58 - 5.16
2tsc 1.52 10 0.6 - - -
3ert 0.58 10 5.4 - - -
3tpi 0.38 10 0.8 0.49 0.80 1.07
4dfr 0.94 10 1.7 1.12 1.44 1.40
5abp 0.43 10 1.2 0.21 - 1.17
6rnt 5.83 0 4.3 2.22 1.20 4.79
7tim 1.25 10 8.7 0.14 0.78 1.49
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Table B.2: Comparison of the docking results (RMSD in A˚) of FlexScreen and AutoDock
for a subset of the 83 complexes. For 14 complexes, we did the calculation with AutoDock
by ourselves, and 11 complexes are from a previous study [23]. These are labeled by ’*’ (2
complexes are the same)
Name FlexScreen AutoDock
1a4q 0.74 1.40
1aqw 0.88 3.84
1abe 0.38 0.16*
1abf 0.58 0.48*
1apt 1.04 1.89*
1apu 0.73 9.10*
1c1e 5.14 9.63
1cil 1.63 5.81*
1mrk 0.86 1.35
1phg 0.28 3.52*
1rds 0.59 4.71
1rnt 1.02 2.04
1snc 6.19 1.97
1srj 7.23 1.85
1tng 0.36 0.62*
1tni 2.80 1.97/2.61*
1tnl 2.73 0.44/0.41*
1ukz 6.21 2.73
2ak3 0.45 5.73
2cpp 0.37 3.40*
2ctc 1.64 1.09
2fox 0.84 1.83
2tsc 1.52 4.46
5abp 0.43 0.48*
6rnt 5.83 1.57
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Table B.3: Median binding energies and affinities (in kJ/mol) for the ligands investigated in
the study of chapter 8. QM designates the quantum mechanical calculated binding energy,
QSF and FSF the median binding energies of the 10 independent docking simulations without
and with (4G) the solvation correction described in the chapter 8. RBA is the measured
relative binding affinity as in [51].
QM QSF FSF MIXED QSF+4G FSF+4G RBA
EST -158 -47 -47 -39 -57 -52 100
DES -112 -38 -49 -36 -50 -54 236
RAL -148 -46 -50 -42 -61 -56 69
OHT -175 -46 -58 -35 -62 -71 257
GEN -39 -38 -54 -38 -45 -52 4
TAM 44 -27 -41 -26 -46 -58 4
OHC -199 -50 -56 -38
CLO 22 -31 -41 -28
ESTA -105 -42 -52 -39 -53 -58 7
BISA 80 -31 -46 -30 -40 -49 0.01
BISF -93 -36 -53 -39

Appendix C
Parameter for the Scoring Function
C.1 Lennard-Jones Parameter
In this section, the atom type parameters for the Lennard-Jones interaction energies are
annotated. As described in section 5.3, the Lennard-Jones interaction energies are expressed
as
ELJij = 4εij
[(
σij
rij
)12
−
(
σij
rij
)6]
. (C.1)
OPLSAA parameter AutoDock parameter
Atom type σii (/nm) ²ii (/ kJMol) σii (/nm) ²ii (/
kJ
Mol)
C 0.35 0.276 0.356 0.63
H 0.225 0.126 0.178 0.08
O 0.312 0.711 0.285 0.84
S 0.355 1.05 0.356 0.84
N 0.325 0.711 0.29 0.67
I 0.35 1.81 0.35 1.81
Cl 0.40 0.494 0.40 0.494
F 0.25 3.01 0.25 3.01
Br 0.41 0.377 0.41 0.377
Li 0.21 0.076 0.21 0.076
Na 0.33 0.012 0.33 0.012
K 0.44 0.002 0.44 0.002
Mg 0.17 3.66 0.17 3.66
Ca 0.24 1.88 0.24 1.88
Zn 0.18 3.66 0.18 3.66
else 0.35 0.276 0.35 0.276
Table C.1: Two sets of Lennard-Jones parameters per atom type: OPLSAA and AutoDock
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The table above lists all the Lennard-Jones parameters per atom type which are used for the
presented studies. We use two parameter sets: either from the OPLSAA force-field [75] or
from the program AutoDock [114].
If interactions of different atom types are considered, the following equations are used to
calculate the Lennard-Jones parameter for mixed atom types:
εab =
√
εaaεaa (C.2)
σab =
√
σaaσbb. (C.3)
C.2 Hydrogen bond parameters
The hydrogen bond energies are calculated, as explained in section 5.3, with
EHBij = cosΘij
(
R˜ij
r12ij
− A˜ij
r10ij
)
+ sinΘij 4εij
[(
σij
rij
)12
−
(
σij
rij
)6]
. (C.4)
Depending on the angle Θij , the van der Waals potential crosses over to a hydrogen bond
specific term. Therefore, we distinguish two different hydrogen bond types and classify them
according to the hydrogen bond donor atom: Either oxygen, nitrogen or sulphur.
We employ the same parameters the program AutoDock [114] also uses. These are listed in
the following table:
Atom type R˜ij (/kJnm
12
Mol ) A˜ij(/
kJnm10
Mol )
N 2.315e-7 7.696e-6
O 2.315e-7 7.696e-6
S 1.247e-6 2.394e-5
Table C.2: Parameters for the hydrogen bond potential
The angle Θij is calculated as described in section 4.1.3.
Appendix D
Used programs and definitions
LATEX
For the thesis the LATEX typeset and the Kile-1.8 integrated environment for LATEX was
used. Accessible via http://www.latex-project.org/ and http://kile.sourceforge.net/
PDB-database
The Protein-Data-Bank (PDB) database [12] is an information portal for macromolecular
structures. It can be accessed via http://www.pdb.org
RMSD
The Root Mean Square Deviation (RMSD) is used to compare two data sets with each other.
In our examples, one data set represents experimental results and the other results of docking
simulations. The RMSD is defined as
RMSD =
√√√√ 1
N
N∑
i=1
(xi − x˜i)2. (D.1)
PyMOL
For all three-dimensional representations of ligands and proteins the program PyMOL [32]
was used.
APBS
The adaptive Poisson-Boltzmann solver (APBS) [8] was used to calculate numerically elec-
trostatic solvation energies under the continuum solvation assumption.
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MOE
The Molecular Operating Environment (MOE) was used for the two-dimensional representa-
tion of protein-ligand complexes.
InsightII
The InsightII molecular modeling environment [70] was used for most of the proteins and
ligands preparations. These preparations consisted of constructing small molecules, of the
protonation of molecules, of assigning partial charges and also of optimizing the geometries
of chemical compounds.
XmGrace
Graphs were plotted using the program XmGrace. XmGrace is developed at the Weizmann
Institute in Israel and runs under GNU General Public License.
http://plasma-gate.weizmann.ac.il/Grace
MSMS
MSMS is a program to calculate molecular surfaces. It is developed by M. Sanner and is
freely available.
In previous FlexScreen versions, the molecular surface calculation was not included and MSMS
was used for that purpose. MSMS was also used for comparing the accuracy of molecular
surface calculations.
Abbreviations
Amino acids
ALA Alanine
ARG Arginine
ASN Asparagine
ASP Aspartic acid
CYS Cysteine
GLN Glutamine
GLU Glutamic acid
GLY Glycine
HIS Histidine
ILE Isoleucine
LEU Leucine
LYS Lysine
MET Methionine
PHE Phenylanaline
PRO Proline
SER Serine
THR Threonine
TRP Tryptophan
TYR Tyrosine
VAL Valine
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TK Thymidine Kinase
Thymidine Kinase ligands
dT deoxythymidine
idu 5-iododeoxyuridine
hpt 6-(3-hydrody-propyl-thymine)
ahiu 5-iodouracil anhydrohexitol nucleoside
mct (North)-methanocarba-thymidine
hmtt 6-[6-hydroxymethy-5-methyl-2,4-dioxo-hexahydro-pyrimidin-
5-yl-methyl]-5-methyl-1H-pyrimidin-2,4-dione
acv aciclovir
gcv ganciclovir
pcv penciclovir
dhbt 6-[3-hydroxy-2-(hydroxymethyl)propyl]-
5-methylpyrimidine-2,4(1H,3H)-dione
ERα Estrogen receptor of subtype α
Estrogen ligands
EST 17β-Estradiol
DES Diethylstilbestrol
RAL Raloxifene
OHT 4-hydroxytamoxifen
GEN Genistein
TAM Tamoxifen
OHC 4-hydroxyclomifene
CLO Clomifene
ESTA 17-Estradiol
BISA Bisphenol A
BISF Bisphenol F
RARγ Retinoic acid receptor of subtype γ
Retinoic acid receptor ligands
AT-RA all-trans retinoic acid
9C-RA 9-cis retinoic acid
CD564 -
BMS181156 -
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MC Monte Carlo
STUN Stochastic tunneling method
SA Simulated Annealing
RMS(D) Root means square (deviation)
MM Molecular mechanics
MD Molecular dynamics
QM Quantum mechanics
FMO Fragmental molecular orbital method
PDB Protein Data Bank
FSF Force field based scoring function
QSF Quantum based scoring function
PMF Potential of mean force
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